U.S. patent application number 11/622312 was filed with the patent office on 2007-05-31 for gene specifically expressed in postmitotic dopaminergic neuron precursor cells.
This patent application is currently assigned to Eisai Co., Ltd.. Invention is credited to Eri Mizuhara, Yasuko Nakagawa, Tomoya Nakatani, Yuichi Ono, Yoshimasa Sakamoto, Yoshimi Takai.
Application Number | 20070122882 11/622312 |
Document ID | / |
Family ID | 32170942 |
Filed Date | 2007-05-31 |
United States Patent
Application |
20070122882 |
Kind Code |
A1 |
Nakagawa; Yasuko ; et
al. |
May 31, 2007 |
GENE SPECIFICALLY EXPRESSED IN POSTMITOTIC DOPAMINERGIC NEURON
PRECURSOR CELLS
Abstract
A novel gene 65B13 expressed specifically and transiently in
dopaminergic neuron precursor cells immediately after cell cycle
exit was obtained by the present invention. The cellular expression
of 65B13 can be used as an index to select cells that are suitable
in terms of their safety, survival rate, and network formation
ability, for transplant therapy of neurodegenerative diseases such
as Parkinson's disease.
Inventors: |
Nakagawa; Yasuko;
(Kyoto-shi, JP) ; Ono; Yuichi; (Kyoto-shi, JP)
; Sakamoto; Yoshimasa; (Kyoto-shi, JP) ; Mizuhara;
Eri; (Kyoto-shi, JP) ; Nakatani; Tomoya;
(Kyoto-shi, JP) ; Takai; Yoshimi; (Kobe-shi,
JP) |
Correspondence
Address: |
TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO
CA
94111-3834
US
|
Assignee: |
Eisai Co., Ltd.
Bunkyo-ku
JP
|
Family ID: |
32170942 |
Appl. No.: |
11/622312 |
Filed: |
January 11, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10532264 |
Dec 28, 2005 |
|
|
|
PCT/JP03/13420 |
Oct 21, 2003 |
|
|
|
11622312 |
Jan 11, 2007 |
|
|
|
Current U.S.
Class: |
435/69.1 ;
435/320.1; 435/325; 530/350; 530/388.22; 536/23.5 |
Current CPC
Class: |
C07K 14/47 20130101;
G01N 33/6896 20130101 |
Class at
Publication: |
435/069.1 ;
536/023.5; 530/350; 530/388.22; 435/320.1; 435/325 |
International
Class: |
C07K 14/705 20060101
C07K014/705; C07K 16/28 20060101 C07K016/28; C07H 21/04 20060101
C07H021/04; C12P 21/06 20060101 C12P021/06 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 22, 2002 |
JP |
2002-307573 |
Claims
1. A polynucleotide comprising a sequence selected from: (i) a
nucleotide sequence comprising nucleotides 177 to 2280 of SEQ ID
NO: 1 or nucleotides 127 to 2079 of SEQ ID NO: 2, or a sequence
complementary to either of said nucleotide sequences; (ii) a
nucleotide sequence encoding the amino acid sequence of SEQ ID NO:
3 or 4, or a sequence complementary to said nucleotide sequence;
(iii) a nucleotide sequence encoding an amino acid sequence in
which a signal sequence portion is deleted in the amino acid
sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said
nucleotide sequence; (iv) a nucleotide sequence encoding an amino
acid sequence with a deletion, insertion, substitution, or addition
of one or more amino acids in the amino acid sequence of SEQ ID NO:
3 or 4, or a sequence complementary to said nucleotide sequence,
wherein the nucleotide sequence has 90% or more identity with a
nucleotide sequence comprising nucleotides 177 to 2280 of SEQ ID
NO: 1 or nucleotides 127 to 2079 of SEQ ID NO: 2; and, (v) a
nucleotide sequence that hybridizes under stringent conditions with
the nucleotide sequence of (i), wherein the nucleotide sequence has
90% or more identity with a nucleotide sequence comprising
nucleotides 177 to 2280 of SEQ ID NO: 1 or nucleotides 127 to 2079
of SEQ ID NO: 2.
2. A vector comprising the polynucleotide of claim 1.
3. A host cell comprising the polynucleotide of claim 1 or the
vector comprising the polynucleotide.
4. A polypeptide encoded by the polynucleotide of claim 1.
5. An antibody against the polypeptide of claim 4 or a fragment of
said polypeptide comprising at least eight amino acid residues.
6. A polynucleotide comprising a sequence selected from: (i) a
nucleotide sequence comprising nucleotides 177 to 2280 of SEQ ID
NO: 1 or nucleotides 127 to 2079 of SEQ ID NO: 2, or a sequence
complementary to either of said nucleotide sequences; (ii) a
nucleotide sequence encoding the amino acid sequence of SEQ ID NO:
3 or 4, or a sequence complementary to said nucleotide sequence;
(iii) a nucleotide sequence encoding an amino acid sequence in
which a signal sequence portion is deleted in the amino acid
sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said
nucleotide sequence; (iv) a nucleotide sequence encoding an amino
acid sequence with a deletion, insertion, substitution, or addition
of one or more amino acids in the amino acid sequence of SEQ ID NO:
3 or 4, or a sequence complementary to said nucleotide sequence;
and, (v) a nucleotide sequence that hybridizes under stringent
conditions with the nucleotide sequence of (i); wherein the
polynucleotide encodes a 65B13 polypeptide expressed specifically
in dopaminergic neuron precursor cells immediately after cell cycle
exit, or an antigenic fragment thereof
7. A vector comprising the polynucleotide of claim 6.
8. A host cell comprising the polynucleotide of claim 6 or the
vector comprising the polynucleotide.
9. A polypeptide encoded by the polynucleotide of claim 6.
10. An antibody against the polypeptide of claim 9 or a fragment of
said polypeptide comprising at least eight amino acid residues.
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 10/532,264, 371 (c) date of Dec. 28, 2005,
which is a U.S. National Phase of PCT/JP03/13420, filed Oct. 21,
2003, which claims priority to Japanese Application No.
2002-307573, filed Oct. 22, 2002. All of the aforementioned
applications are hereby incorporated by reference in their
entireties and for all purposes.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED
RESEARCH OR DEVELOPMENT
[0002] NOT APPLICABLE
REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM
LISTING APPENDIX SUBMITTED ON A COMPACT DISK
[0003] NOT APPLICABLE
BACKGROUND OF THE INVENTION
[0004] 1. Technical Field
[0005] The present invention relates to the novel 65B13 gene
expressed in postmitotic dopaminergic neurons. Dopaminergic neuron
precursor cells used in transplant therapy for neurodegenerative
diseases such as Parkinson's disease (PD) can be efficiently
isolated by detecting this gene.
[0006] 2. Background Art
[0007] The dopamine system is an extremely important system for
essential motor regulation, hormone secretion regulation, emotion
regulation, and such in the mammalian brain. Thus, abnormalities in
dopaminergic neural transmission cause various neural disorders.
For example, Parkinson's disease (PD) is a neurodegenerative
disease of the extrapyramidal system that occurs due to specific
degeneration of dopaminergic neurons in the substantia nigra of the
midbrain (Harrison's Principles of Internal Medicine, Vol. 2, 23rd
edition, Isselbacher et al., ed., McGraw-Hill Inc., NY (1994), pp.
2275-7). Oral administration of L-DOPA (3,4-dihydroxyphenylalanine)
is performed as a primary therapeutic method to compensate for the
decrease in the amount of dopamine produced; however, the duration
of the effect is known to be unsatisfactory.
[0008] More recently, a therapeutic method in which the midbrain
ventral zone of 6 to 9-week old aborted fetuses containing
dopaminergic neuron progenitor cells are transplanted to compensate
for the loss of dopaminergic neurons was attempted (U.S. Pat. No.
5,690,927; Spencer et al. (1992) N. Engl. J. Med. 327: 1541-8;
Freed et al. (1992) N. Engl. J. Med. 327: 1549-55; Widner et al.
(1992) N. Engl. J. Med. 327: 1556-63; Kordower et al. (1995) N.
Engl. J. Med. 332: 1118-24; Defer et al. (1996) Brain 119: 41-50;
Lopez-Lozano et al. (1997) Transp. Proc. 29: 977-80). However, in
addition to cell supply and ethical issues (Rosenstain (1995) Exp.
Neurol. 33: 106; Turner et al. (1993) Neurosurg. 33: 1031-7), this
method is currently under criticism for various other problems,
including risk of infection and contamination, immunological
rejection of transplants (Lopez-Lozano et al. (1997) Transp. Proc.
29: 977-980; Widner and Brudin (1988) Brain Res. Rev. 13: 287-324),
and low survival rates due to fetal tissues' primary dependence on
the lipid metabolism rather than glycolysis (Rosenstein (1995) Exp.
Neurol. 33: 106).
[0009] In order to resolve the ethical issues and shortage of
supply, methods have been proposed that use, for example, porcine
cortex, stria, or midbrain cells (for example, Published Japanese
Translation of International Publication No. Hei 10-508487,
Published Japanese Translation of International Publication No. Hei
10-508488 or Published Japanese Translation of International
Publication No. Hei 10-509034). In these methods, a complex
procedure that involves the alteration of cell surface antigens
(MHC class I antigens) is required. Therefore, the use of an in
vitro differentiation system to generate dopaminergic neurons from
non-neural cells such as embryonic stem (ES) cells and bone marrow
interstitial cells instead of cells derived from aborted fetuses,
is considered promising. The importance of regeneration therapy
using ES cells or a patient's own neural stem cells is likely to
grow in the future. A method involving local immunosuppression by
simultaneously transplanting Sertoli's cells has been proposed as a
method of eliminating transplant rejection (Published Japanese
Translation of International Publication No. Hei 11-509170,
Published Japanese Translation of International Publication No. Hei
11-501818, Selawry and Cameron (1993) Cell Transplant 2: 123-9). It
is possible to obtain transplant cells from relatives that have
matching MHCs, bone marrow from other individuals, bone marrow
banks, or umbilical cord-blood banks. However, if it were possible
to use the patient's own cells, the problem of rejection reactions
can be overcome without any laborious procedures and trouble.
[0010] An additional problem is the possibility that neuron
progenitor cells may differentiate into groups of heterogeneous
cells. In treating Parkinson's disease, it is necessary to
selectively transplant those catecholamine-containing neurons that
produce dopamine. Examples of transplant cells that have been
proposed in the past for use in the treatment of Parkinson's
disease include striatum (Lindvall et al. (1989) Arch. Neurol. 46:
615-31; Widner et al. (1992) N. Engl. J. Med. 327: 1556-63),
immortalized cell lines derived from human fetal neurons (Published
Japanese Translation of International Publication No. Hei 8-509215;
Published Japanese Translation of International Publication No. Hei
11-506930; Published Japanese Translation of International
Publication No. 2002-522070), human postmitotic neurons derived
from NT2Z cells (Published Japanese Translation of International
Publication No. Hei 9-5050554), primordial neuron cells (Published
Japanese Translation of International Publication No. Hei
11-509729), and cells and bone marrow stroma cells transfected with
exogenous genes so as to produce catecholamines such as dopamines
(Published Japanese Translation of International Publication No.
2002-504503; Published Japanese Translation of International
Publication No. 2002-513545). However, none of these contain only
the dopaminergic neurons or cells that differentiate into
dopaminergic cells.
[0011] A method has been proposed for selectively concentrating and
isolating dopaminergic neurons from undifferentiated cell
populations. In this method, a reporter gene that expresses a
fluorescent protein is introduced into each cell of the cell
population, under the control of a promoter/enhancer of genes, such
as the tyrosine hydroxylase expressed in dopaminergic neurons, and
then cells that emit fluorescence are isolated. The dopaminergic
neurons are visualized in their viable state, and concentrated,
isolated, and identified (Unexamined Published Japanese Patent
Application No. 2002-51775). This method requires the step of
introducing an exogenous gene, and further, the presence of a
reporter gene poses problems of toxicity and immunogenicity for use
in gene therapy.
BRIEF SUMMARY OF THE INVENTION
Disclosure of the Invention
[0012] One of the major problems in Parkinson's disease (PD)
transplant therapy at the moment is that in vitro differentiated
dopaminergic neuron precursor cells and midbrain ventral zone of
aborted fetuses are both mixtures of myriad types of cells. When
considering the safety in neural circuit formation, it is
preferable to use isolated cells that comprise only the cell type
of interest. Furthermore, when considering the risk of
tumorigenesis, it is believed that it would be better to use
isolated postmitotic neuron. Moreover, when considering the
survival of cells at their transplant site in the brain, and their
ability to properly form a network, it is expected that therapeutic
effects can be further improved by isolating precursor cells at as
early a stage as possible. Therefore, the inventors of the present
invention aimed to isolate a gene specific to dopaminergic neuron
precursor cells.
[0013] In order to isolate a gene specific to dopaminergic neuron
precursor cells, genes with differential expressions were amplified
by improving the subtraction method (N-RDA; representational
differential analysis method; RDA method (Listsyn N A (1995) Trends
Genet. 11: 303-7)), ("Method for Homogenizing the Amount of DNA
Fragments and Subtraction Method", Japanese Patent Application No.
2001-184757 (filing date: Jun. 19, 2001)) using E12.5 mouse ventral
and dorsal midbrain RNA, and analyzing the sequences of the
amplified genes. As a result, the novel gene 65B13 was obtained.
Two alternative isoforms, named 65B13-a and 65B13-b, were also
obtained from determining the gene's full-length sequence by the
RACE method. The nucleotide sequences of the isoforms are
designated as SEQ ID NO: 1 and SEQ ID NO: 2. The amino acid
sequences of proteins encoded by the nucleotide sequences are
indicated as SEQ ID NO: 3 and SEQ ID NO: 4, respectively (FIGS. 1
to 4).
[0014] The in situ hybridization results were further supported by
immunostaining using an anti-65B 13 antibody (FIG. 13). Moreover,
populations of cells expressing 65B13 could be efficiently
separated by flow cytometry using an anti-65B13 antibody (FIG.
14).
[0015] According to the above results, anti-65B13 antibodies can be
used to obtain pure early-stage dopaminergic neuron precursor
cells, by isolating 65B13-expressing cells from ventral midbrain
region or cell cultures that contain in vitro-differentiated
dopaminergic neurons. Cells obtained in this manner contain only
postmitotic precursor cells, and since only the cell type of
interest is isolated, these cells are extremely safe even when used
for transplant therapy. Since the earliest possible precursor cells
are used, high therapeutic efficacy can be expected in terms of
their survival rate, network formation ability, and such. Further,
in the cases where the best therapeutic effects cannot be achieved
by these early precursor cells obtained immediately after cell
cycle exit, and where the use of matured cells is required, early
precursor cells obtained by this method can simply be cultured in
vitro to mature into a suitable stage of differentiation. Thus,
materials that are in a differentiation stage suitable for the
target transplant therapy can be easily prepared (FIG. 12).
[0016] Moreover, pure dopaminergic neuron precursor cells are also
useful for the search of therapeutic targets for Parkinson's
disease, isolation of genes specific for dopaminergic neurons
precursor cells or stage-specific genes during the maturation of
dopaminergic neuron precursor cells, and the like. In addition, the
earliest possible precursor cells obtained using the methods of the
present invention can also be used to unravel the maturation
process of dopaminergic neurons, to screening systems using
maturation as an indicator, and such.
[0017] More specifically, the present invention relates to:
[0018] [1] a polynucleotide that comprises a sequence selected from
the nucleotide sequences of (1) to (5), wherein the nucleotide
sequences encode 65B13 polypeptide expressed specifically in
dopaminergic neuron precursor cells immediately after cell cycle
exit, or antigenic fragment thereof: [0019] (1) a nucleotide
sequence that comprises the 177th to 2280th nucleotides of SEQ ID
NO: 1 or the 127th to 2079th nucleotides of SEQ ID NO: 2, or
sequence complementary to said nucleotide sequence; [0020] (2) a
nucleotide sequence that encodes the amino acid sequence of SEQ ID
NO: 3 or 4, or sequence complementary to said nucleotide sequence;
[0021] (3) a nucleotide sequence that encodes the amino acid
sequence of SEQ ID NO: 3 or 4, wherein a signal sequence portion is
deleted, or sequence complementary to said nucleotide sequence;
[0022] (4) a nucleotide sequence that encodes the amino acid
sequence of SEQ ID NO: 3 or 4, wherein one or more amino acids have
been deleted, inserted, substituted, or added, or sequence
complementary to said nucleotide sequence; and, [0023] (5) a
nucleotide sequence that hybridizes with the nucleotide sequence
(1) under stringent conditions; [2] a vector that comprises the
polynucleotide of [1]; [3] a host cell that comprises the
polynucleotide of [1] or the vector of [2]; [4] a polypeptide that
is encoded by the polynucleotide of [1]; [5] a fragment of the
polypeptide of [4], wherein the polypeptide fragment comprises at
least eight amino acid residues; [6] an antibody against the
polypeptide of [4] or the polypeptide fragment of [5]; [7] a
nucleotide chain that encodes the polypeptide fragment of [5]; [8]
a method for selecting a dopaminergic neuron, wherein the method
comprises the step of contacting the antibody of [6] with a cell
sample thought to comprise a dopaminergic neuron precursor cell;
[9] a method for selecting a dopaminergic neuron, wherein the
method comprises the step of contacting a peptide comprising at
least the extracellular portion of the polypeptide of [4] with a
cell sample thought to comprise a dopaminergic neuron precursor
cell; [10] a Dopaminergic neuron precursor cell immediately after
cell cycle exit, wherein the cell is selected by the method of [8]
or [9]; [11] a method for isolating a gene specific to a
dopaminergic neuron precursor cell, and a gene specific to each
stage of maturation into a dopaminergic neurons, wherein the method
comprises the step of: detecting and isolating a gene specifically
expressed in the precursor cell of [10] or a cell differentiated,
induced, or proliferated from said precursor cell; and [12] a
method for screening using maturation as an indicator, wherein the
method comprises the steps of: contacting a test substance with the
precursor cell of [10]; and detecting the differentiation or
proliferation of the precursor cell resulting from the contacting
step.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] FIG. 1 shows the cDNA sequence and the amino acid sequence
of 65B13-a. The signal sequence and transmembrane domain are
underlined.
[0025] FIG. 2 shows the cDNA sequence and the amino acid sequence
of 65B13-a. The signal sequence and transmembrane domain are
underlined. This drawing is a continuation of FIG. 1.
[0026] FIG. 3 shows the cDNA sequence and the amino acid sequence
of 65B13-b. The signal sequence and transmembrane domain are
underlined.
[0027] FIG. 4 shows the cDNA sequence and the amino acid sequence
of 65B13-b. The signal sequence and transmembrane domain are
underlined. This drawing is a continuation of FIG. 3.
[0028] FIG. 5 is comparison of the amino acid sequences of 65B13-a
and 65B13-b.
[0029] FIG. 6 is a schematic diagram of 65B13 structure. The shaded
areas indicate the transmembrane domain, while Ig represents the Ig
domain.
[0030] FIG. 7 is a set of photographs showing the results of 65B13
mRNA expression analysis in E12.5 mouse brain by in situ
hybridization. A: Sagittal cross-section, B: Parasagittal
cross-section, HB: Hindbrain, MB: Midbrain, SC: Spinal cord, CB:
Cerebellar primordium.
[0031] FIG. 8 is a set of photographs showing the results of 65B13
mRNA expression analysis in E12.5 mouse spinal cord by in situ
hybridization. A: 65B13, B: NCAM, C: Comparison of the expression
regions of 65B13, Ki67, and NCAM (shown as enlarged pictures of
framed regions in A and B).
[0032] FIG. 9 is a set of photographs showing the results of 65B13
mRNA expression analysis in the ventral midbrain region of E12.5
mice, and tyrosine hydroxylase (TH) mRNA expression analysis by in
situ hybridization. A: 65B13, B: TH.
[0033] FIG. 10 is a schematic diagram showing the expression
pattern of 65B13 in the midbrain.
[0034] FIG. 11 is a schematic diagram showing the 65B13 expression
pattern over time.
[0035] FIG. 12 is a schematic diagram demonstrating the methods for
separating and utilizing dopaminergic neuron precursor cells using
an anti-65B13 antibody.
[0036] FIG. 13 is a photograph showing the expression analysis
results of 65B13 (Cy3), Nurr1 (FITC), and TH (Cy5) proteins, by the
immunofluorescent staining method using antibodies against each
protein.
[0037] FIG. 14 is a set of graphs showing the flow-cytometric
analysis results of detecting 65B13-expressing cells with a 65B13
monoclonal antibody in the (A) ventral midbrain region of E12.5
mouse embryo, and (B) cell populations comprising dopaminergic
neuron precursor cells differentiated from ES cells in vitro.
DETAILED DESCRIPTION OF THE INVENTION
<Polynucleotides>
[0038] Polynucleotides of the present invention can be applied to
generate antigens by genetic engineering techniques to produce
antibodies that can be used for the selection of dopaminergic
neuron precursor cells. A polynucleotide of the present invention
encodes the 65B13 polypeptide specifically expressed in
dopaminergic neuron precursor cells immediately after cell cycle
exit, and comprises nucleotides 177 to 2280 of SEQ ID NO: 1 (FIGS.
1 and 2), nucleotides 127 to 2079 of SEQ ID NO: 2 (FIGS. 3 and 4),
or a sequence complementary to either of these sequences.
[0039] Here, a "polynucleotide" refers to a polymer comprising
nucleotides or nucleotide pairs of multiple deoxyribonucleic acids
(DNA) or ribonucleic acids (RNA), and includes DNA, cDNA, genomic
DNA, chemically synthesized DNA, and RNA. If needed,
polynucleotides can also contain non-naturally-occurring
nucleotides such as 4-acetylcytidine,
5-(carboxyhydroxymethyl)uridine, 2'-O-methylcytidine,
5-carboxymethylaminomethyl-2-thiouridine,
5-carboxymethylaminomethyluridine, dihydrouridine,
2'-O-methylpseudouridine, .beta.-D-galactosylqueuosine,
2'-O-methylguanosine, inosine, N6-isopentenyladenosine,
1-methyladenosine, 1-methylpseudouridine, 1-methylguanosine,
1-methylinosine, 2,2-dimethylguanosine, 2-methyladenosine,
2-methylguanosine, 3-methylcytidine, 5-methylcytidine,
N6-methyladenosine, 7-methylguanosine, 5-methylaminomethyluridine,
5-methoxyaminomethyl-2-thiouridine, .beta.-D-mannosylqueuosine,
5-methoxycarbonylmethyl-2-thiouridine,
5-methoxycarbonylmethyluridine, 5-methoxyuridine,
2-methylthio-N6-isopentenyladenosine,
N-((9-.beta.-D-ribofuranosyl-2-methylthiopurin-6-yl)carbamoyl)threonine,
N-((9-.beta.-D-ribofuranosylpurin-6-yl)N-methylcarbamoyl)threonine,
uridine-5-oxyacetic acid-methyl ester, uridine-5-oxyacetic acid,
wybutoxosine, pseudouridine, queuosine, 2-thiocytidine,
5-methyl-2-thiouridine, 2-thiouridine, 4-thiouridine,
5-methyluridine,
N-((9-.beta.-D-ribofuranosylpurin-6-yl)carbamoyl)threonine,
2'-O-methyl-5-methyluridine, 2'-O-methyluridine, wybutosine, and
3-(3-amino-3-carboxy propyl)uridine.
[0040] Moreover, a polynucleotide of the present invention encodes
the 65B13 polypeptide specifically expressed in dopaminergic neuron
precursor cells immediately after cell cycle exit, and comprises an
amino acid sequence described in SEQ ID NO: 3 (FIGS. 1, 3 and 5) or
SEQ ID NO: 4 (FIGS. 2, 4 and 5), or a complementary sequence
thereof. In addition to the nucleotide sequences described in SEQ
ID NOs: 1 and 2, nucleotide sequences encoding such an amino acid
sequences include those that differ from the sequences described in
SEQ ID NOs: 1 and 2 due to degeneracy of the genetic code. A
polynucleotide of the present invention can be designed to express
a polypeptide using genetic engineering techniques, by selecting a
nucleotide sequence that has a high expression efficiency in view
of the host's codon usage frequency (Grantham et al. (1981) Nucleic
Acids Res. 9: 43-74). The polynucleotides of the present invention
also comprise a nucleotide sequence encoding an amino acid sequence
lacking the signal sequence portion of the amino acid sequence
described in SEQ ID NO: 3 or 4. The first 17 amino acid residues of
the amino acid sequence of SEQ ID NO: 3 or 4 correspond to a signal
sequence.
[0041] The polynucleotides of the present invention also comprise a
nucleotide sequence encoding the 65B13 polypeptide specifically
expressed in dopaminergic neuron precursor cells immediately after
cell cycle exit, or an antigenic fragment thereof, wherein one or
more amino acids in the amino sequence of SEQ ID NO: 3 or 4 are
deleted, inserted, substituted, or added, or a sequence
complementary to this nucleotide sequence. It is well known that a
mutant polypeptide comprising an amino acid sequence, in which one
or more amino acids are deleted, inserted, substituted, or added,
maintain the same biological activity as the original polypeptide
(Mark et al. (1984) Proc. Natl. Acad. Sci. USA 81: 5662-6; Zoller
and Smith (1982) Nucleic Acids Res. 10: 6487-500; Wang et al.
(1984) Science 224: 1431-3; Dalbadie-McFarland et al. (1982) Proc.
Natl. Acad. Sci. USA 79: 6409-13).
[0042] Here, an amino acid substitution refers to a mutation in
which one or more amino acid residues in a sequence are changed to
a different type of amino acid residue. When the amino acid
sequence encoded by a polynucleotide of the present invention is
altered by such a substitution, a conservative substitution is
preferably carried out if the function of the protein is to be
maintained. A conservative substitution means altering a sequence
so that it encodes an amino acid that has properties similar to
those of the amino acid before substitution. Amino acids can be
classified, based on their properties, into non-polar amino acids
(Ala, Ile, Leu, Met, Phe, Pro, Trp, Val), non-charged amino acids
(Asn, Cys, Gln, Gly, Ser, Thr, Tyr), acidic amino acids (Asp, Glu),
basic amino acids (Arg, His, Lys), neutral amino acids (Ala, Asn,
Cys, Gln, Gly, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val),
aliphatic amino acids (Ala, Gly), branched amino acids (Ile, Leu,
Val), hydroxyamino acids (Ser, Thr), amide-type amino acids (Gln,
Asn), sulfur-containing amino acids (Cys, Met), aromatic amino
acids (His, Phe, Trp, Tyr), heterocyclic amino acids (His, Trp),
imino acids (Pro, 4Hyp), and such. In particular, substitutions
among Ala, Val, Leu, and Ile; Ser and Thr; Asp and Glu; Asn and
Gln; Lys and Arg; and Phe and Tyr, are preferable in order to
maintain protein properties. There are no particular limitations on
the number and sites of the mutated amino acids, as long as the
amino acid encoded by the polynucleotide has 65B13
antigenicity.
[0043] A polynucleotide encoding an amino acid sequence, in which
one or more amino acids are deleted, inserted, substituted, or
added to the sequence of SEQ ID NO: 3 or 4, can be prepared
according to methods such as site-directed mutagenesis described in
(Molecular Cloning, A Laboratory Manual 2.sup.nd ed. (Cold Spring
Harbor Press (1989)), Current Protocols in Molecular Biology (John
Wiley & Sons (1987-1997); especially Section 8.1-8.5),
Hashimoto-Goto et al. (1995) Gene 152: 271-5, Kunkel (1985) Proc.
Natl. Acad. Sci. USA 82: 488-92, Kramer and Fritz (1987) Method.
Enzymol. 154: 350-67, Kunkel (1988) Method. Enzymol. 85: 2763-6),
and others.
[0044] Moreover, a polynucleotide of the present invention is a
polynucleotide comprising a nucleotide sequence that hybridizes
under stringent conditions with a nucleotide sequence comprising
nucleotides 177 to 2280 of SEQ ID NO: 1 or nucleotides 127 to 2079
of SEQ ID NO: 2, or a sequence complementary to either of these
sequences, wherein the polynucleotide encodes a 65B13 polypeptide
specifically expressed in dopaminergic neuron precursor cells
immediately after cell cycle exit, or an antigenic fragment
thereof. In addition to the two 65B13 isoforms having sequences
represented by SEQ ID NOs: 1 and 2 obtained in the Examples of the
present invention, alternative isoforms and allelic mutations may
also exist. Thus, such alternative isoforms and allelic mutations
are also included in polypeptides of the present invention. Such
polypeptides can be obtained from cDNA libraries or genomic
libraries derived from animals such as humans, mice, rats, rabbits,
hamsters, chickens, pigs, cows, goats, and sheep, by using a
polynucleotide probe consisted of a nucleotide sequence comprising
nucleotides 177 to 2280 of SEQ ID NO: 1 or nucleotides 127 to 2079
of SEQ ID NO: 2, in known hybridization methods such as colony
hybridization, plaque hybridization, or Southern blotting. See
"Molecular Cloning, A Laboratory Manual 2nd ed." (Cold Spring
Harbor Press (1989)) for methods of cDNA library construction. In
addition, a commercially available cDNA library or genomic library
may also be used.
[0045] More specifically, in constructing a cDNA library, total RNA
is first prepared from cells, organs, tissues, or such that express
a polynucleotide of the present invention, by known techniques such
as guanidine ultracentrifugation (Chirwin et al. (1979)
Biochemistry 18: 5294-5299) or AGPC (Chomczynski and Sacchi (1987)
Anal. Biochem. 162: 156-159), followed by purification of mRNA
using the mRNA Purification Kit (Pharmacia), or such. A kit for
direct mRNA preparation, such as the QuickPrep mRNA Purification
Kit (Pharmacia), may also be used. Next, cDNA is synthesized from
the resulting mRNA using reverse transcriptase. cDNA synthesis kits
such as the AMV Reverse Transcriptase First-strand cDNA Synthesis
Kit (Seikagaku Corporation) are also available commercially. Other
methods that use the 5'-RACE method to synthesize and amplify cDNA
by PCR may also be used (Frohman et al. (1988) Proc. Natl. Acad.
Sci. USA 85: 8998-9002; Belyavsky et al. (1989) Nucleic Acids Res.
17: 2919-32). In addition, in order to construct cDNA libraries
containing a high percentage of full-length clones, known
techniques such as the oligo-capping method (Maruyama and Sugano
(1994) Gene 138: 171-4; Suzuki (1997) Gene 200: 149-56) can also be
employed. The cDNA obtained in this manner is then incorporated
into a suitable vector.
[0046] Examples of hybridization conditions in the present
invention include "2.times.SSC, 0.1% SDS, 50.degree. C.",
"2.times.SSC, 0.1% SDS, 42.degree. C." and "1.times.SSC, 0.1% SDS,
37.degree. C.". Examples of conditions of higher stringency include
"2.times.SSC, 0.1% SDS, 65.degree. C.", "0.5.times.SSC, 0.1% SDS,
42.degree. C." and "0.2.times.SSC, 0.1% SDS, 65.degree. C.". More
specifically, a method that uses the Rapid-hyb buffer (Amersham
Life Science) can be carried out by performing pre-hybridization at
68.degree. C. for 30 minutes or more, adding a probe to allow
hybrid formation at 68.degree. C. for 1 hour or more, washing three
times in 2.times.SSC/0.1% SDS at room temperature for 20 minutes
each, washing three times in 1.times.SSC/0.1% SDS at 37.degree. C.
for 20 minutes each, and finally washing twice in 1.times.SSC/0.1%
SDS at 50.degree. C. for 20 minutes each. This can also be carried
out using, for example, the Expresshyb Hybridization Solution
(CLONTECH), by performing pre-hybridization at 55.degree. C. for 30
minutes or more, adding a labeled probe and incubating at
37.degree. C. to 55.degree. C. for 1 hour or more, washing three
times in 2.times.SSC/0.1% SDS at room temperature for 20 minutes
each, and washing once at 37.degree. C. for 20 minutes with
1.times.SSC/0.1% SDS. Here, conditions of higher stringency can be
achieved by increasing the temperature for pre-hybridization,
hybridization, or second wash. For example, a pre-hybridization and
hybridization temperature of 60.degree. C. can be raised to
68.degree. C. for higher stringency. In addition to factors such as
salt concentration of the buffer and temperature, a person with
ordinary skill in the art can also integrate other factors such as
probe concentration, probe length, and reaction time, to obtain
murine 65B13 isoforms and allelic mutants attained in the Examples
of the present invention, and corresponding genes derived from
other organisms.
[0047] References such as Molecular Cloning, A Laboratory Manual
2.sup.nd ed. (Cold Spring Harbor Press (1989); Section 9.47-9.58),
Current Protocols in Molecular Biology (John Wiley & Sons
(1987-1997); Section 6.3-6.4), DNA Cloning 1: Core Techniques, A
Practical Approach 2.sup.nd ed. (Oxford University (1995); Section
2.10 for conditions, in particular), can be referred to for
detailed information on hybridization procedures. Examples of
hybridizing polynucleotides include polynucleotides containing a
nucleotide sequence that has at least 50% or more, preferably 70%,
more preferably 80% and even more preferably 90% (for example, 95%
or more, or 99%) identity with a nucleotide sequence comprising
nucleotides 177 to 2280 of SEQ ID NO: 1 or nucleotides 127 to 2079
of SEQ ID NO: 2. Such identities can be determined by the BLAST
algorithm (Altschul (1990) Proc. Natl. Acad. Sci. USA 87: 2264-8;
Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-7).
Examples of programs that have been developed based on this
algorithm include the BLASTX program for determining the identity
of amino acid sequences, and the BLASTN program for nucleotide
sequences (Altschul et al. (1990) J. Mol. Biol. 215: 403-10). These
programs can be used for the sequences of the present invention
(see http://www.ncbi.nlm.nih.gov. for a specific example of
analysis methods).
[0048] 65B13 isoforms or allelic mutants, and other genes with a
65B13-like structure or function, can be obtained from cDNA
libraries and genome libraries of animals such as humans, mice,
rats, rabbits, hamsters, chickens, pigs, cows, goats, and sheep, by
designing primers based on the nucleotide sequences of SEQ ID NOs:
1 and 2, using gene amplification technology (PCR) (Current
Protocols in Molecular Biology, John Wiley & Sons (1987)
Sections 6.1-6.4).
[0049] For example, BLAST search results revealed three human
sequences of unknown function that are 84% identical to the
nucleotide sequence of mouse 65B13 of the present invention
(GenBank Accession No.: XM.sub.--048304, AL136654, BC007312). The
respective nucleotide sequences are listed as SEQ ID NOs: 5, 7, and
9, with their predicted amino acid sequences listed as SEQ ID NOs:
6, 8, and 10, and are considered human homologues of mouse 65B13.
According to the methods of the present invention, such human
homologues can be used to select human dopaminergic neuron
precursor cells. All three sequences are believed to be sequences
derived from the same gene on chromosome 19, based on reported
information. Among them, two sequences AL136654 (SEQ ID NO: 7) and
BC007312 (SEQ ID NO: 9) are cDNA fragments, while the third
sequence XM.sub.--048304 (SEQ ID NO: 5) is considered an mRNA
sequence predicted from the genome sequence. These predicted
sequences have ORFs that are similar in size to 65B13 of the
present invention, and the predicted amino acid sequences share an
84% identity with 65B13.
[0050] The polynucleotide sequences of the present invention can be
confirmed by using conventional sequence determination methods. For
example, the dideoxynucleotide chain termination method (Sanger et
al. (1977) Proc. Natl. Acad. Sci. USA 74: 5463) can be used. In
addition, sequences can also be analyzed using a suitable DNA
sequencer.
<Nucleotide Chains>
[0051] Moreover, a nucleotide chain complementary to a
polynucleotide of the present invention comprising at least 15
nucleotides is provided by the present invention. Here, a
"complementary sequence" refers to not only cases where at least 15
consecutive nucleotides of the nucleotide sequence completely pair
with the template, but also includes those that have at least 70%,
preferably 80%, more preferably 90% and even more preferably 95% or
more (for example, 97% or 99%) of the consecutive nucleotides
paired with the template. Pair formation refers to the formation of
a chain, in which T (U in the case of an RNA) corresponds to A, A
corresponds to T or U, G corresponds to C, and C corresponds to G
in the nucleotide sequence of the template polynucleotide.
Identities can be determined by methods similar to that used in the
aforementioned polynucleotide hybridization.
[0052] Such a nucleotide chain of the present invention can be used
as a probe for detecting or isolating, or as a primer for
amplifying the polynucleotides of the present invention. The
nucleotide chain normally consists of 15 to 100, and preferably 15
to 35 nucleotides when used as a probe, or at least 15 and
preferably 30 nucleotides when used as a primer. A primer can be
designed to have a restriction enzyme recognition sequence, a tag
or such, added to the 5'-end side thereof, and at the 3' end, a
sequence complementary to a target sequence. A nucleotide chain of
the present invention can hybridize with a polynucleotide of the
present invention. Moreover, mutations of a polynucleotide of the
present invention within cells can be detected using these probes
or primers. In some cases, such mutations may cause abnormalities
in the activity or expression of the polypeptides of the present
invention, therefore, nucleotide chains of the present inventions
are thought to be useful for disease diagnosis and such.
[0053] In addition, the nucleotide chains of the present invention
include antisense nucleic acids that suppress the cellular
expression of a polynucleotide of the present invention by binding
to an mRNA or DNA, and ribozymes that suppress via specific
cleavage of mRNA.
[0054] Examples of antisense mechanisms to suppress target gene
expression include: (1) inhibition of transcription initiation via
triplex formation, (2) transcription suppression through hybrid
formation at sites of local open-loop structure formed by RNA
polymerases, (3) transcription inhibition through hybrid formation
with RNA during synthesis, (4) suppression of splicing through
hybrid formation at intron-exon junctions, (5) suppression of
splicing through hybrid formation at sites of spliceosome
formation, (6) suppression of mRNA migration to the cytoplasm
through hybrid formation with mRNA, (7) suppression of splicing
through hybrid formation at a capping site or poly A addition site,
(8) suppression of translation initiation through hybrid formation
at the binding sites of initiation factors, (9) translation
suppression through hybrid formation at ribosome binding sites,
(10) suppression of peptide chain elongation through hybrid
formation at mRNA coding regions or polysome binding sites, and
(11) suppression of gene expression through hybrid formation at
sites of nucleic acid/protein interaction (Hirashima and Inoue,
"New Biochemistry Experiment Course 2, Nucleic Acids IV, Gene
Replication and Expression", Japanese Biochemical Society edit.,
Tokyo Kagaku Dozin Publishing, pp. 319-347 (1993)).
[0055] An antisense nucleic acid contained in a nucleotide chain of
the present invention may be a nucleic acid that inhibits gene
expression by any of the mechanisms described in (1) to (11) above.
Namely, it may contain an antisense sequence to not only the coding
region, but also to a non-coding region sequence of a target gene
whose expression is to be inhibited. A DNA that encodes an
antisense nucleic acid can be used by linking to a suitable
regulatory sequence that allows its expression. The antisense
nucleic acid does not need to be completely complementary to the
coding region or non-coding region of a target gene, as long as it
can effectively inhibit the expression of the gene. Such antisense
nucleic acids have a chain length of at least 15 bp or more,
preferably 100 bp or more, and more preferably 500 bp or more, and
are normally within 3000 bp, preferably within 2000 bp and more
preferably within 1000 bp. It is preferred that such antisense
nucleic acids share an identity of 90% or more, and more preferably
95% or more, with the complementary chain of a target gene
transcription product. These antisense nucleic acids can be
prepared according to the phosphothionate method (Stein (1988)
Nucleic Acids Res. 16: 3209-3221) using the polynucleotides of the
present invention.
[0056] "Ribozyme" is a generic term referring to catalysts with an
RNA component, and ribozymes are broadly classified into large
ribozymes and small ribozymes. Large ribozymes are enzymes that
cleave the phosphate-ester bonds of a nucleic acid and leave the
reaction sites with 5'-phosphoric acid and 3'-hydroxyl group at the
end of a reaction. Large ribozymes are further classified into (1)
group I intron RNAs, which undergo guanosine-initiated
trans-esterification reactions at 5'-spliced sites, (2) group II
intron RNAs, which undergo two-step self-splicing reactions with a
resultant lariat structure, and (3) RNA components of ribonuclease
P, which cleave precursor tRNAs at their 5' side via hydrolysis
reactions. In contrast, small ribozymes are comparatively small
structural units (about 40 bp) that cleave RNAs, forming
5'-hydroxyl groups and 2'-3' cyclic phosphoric acids. Small
ribozymes include, for example, hammerhead-type ribozymes (Koizumi
et al. (1988) FEBS Lett. 228: 225) and hairpin-type ribozymes
(Buzayan (1986) Nature 323: 349; Kikuchi and Sasaki (1992) Nucleic
Acids Res. 19: 6571; H. Kikuchi (1992) Chemistry and Biology 30:
112). Since ribozymes are easily altered and synthesized, various
modification methods are known. For example, hammerhead-type
ribozymes that recognize and cleave nucleotide sequence UC, UU, or
UA within a target RNA can be created, by designing the substrate
binding portion of a ribozyme to be complementary to an RNA
sequence near the target site (Koizumi et al. (1988) FEBS Lett.
228: 225; M. Koizumi and E. Ohtsuka (1990) Protein, Nucleic Acid,
and Enzyme 35: 2191; Koizumi et al. (1989) Nucleic Acids Res. 17:
7059). Hairpin-type ribozymes can also be designed and produced
using known methods (Kikuchi and Sasaki (1992) Nucleic Acids Res.
19: 6571; H. Kikuchi (1992) Chemistry and Biology 30: 112).
[0057] Antisense nucleic acids and ribozymes comprised in the
nucleotide chains of the present invention can also be used as
virus vectors derived from retroviruses, adenoviruses,
adeno-associated viruses, and such, non-virus vectors that use
liposomes, or naked DNAs, to control gene expression in cells using
ex vivo or in vivo methods for gene therapy.
[0058] The nucleotide sequences of the nucleotide chains of the
present invention can be confirmed by the same methods used for the
aforementioned polynucleotides.
<Vectors>
[0059] Vectors comprising a polynucleotide of the present invention
are provided by the present invention. A vector of the present
invention is useful for carrying a polynucleotide of the present
invention within host cells, or for expressing a polypeptide
encoded by the polynucleotide. This vector includes various vectors
such as plasmids, cosmids, viruses, bacteriophages, cloning
vectors, and expression vectors (Molecular Cloning, A Laboratory
Manual 2.sup.nd ed., Cold Spring Harbor Press (1989); Current
Protocols in Molecular Biology, John Wiley & Sons (1987)). In a
preferred embodiment, a polynucleotide of the present invention is
expressed in a host cell, into which a vector of the present
invention has been introduced, by linking to the downstream of a
regulatory sequence. Here, "regulatory sequence" includes
promoters, ribosome binding sites, and terminators in the case of a
prokaryotic host cell, and promoters and terminators in the case of
a eukaryotic host cell, and in some cases, may also contain
transactivators, transcription factors, poly A signals which
stabilize transcription products, splicing and polyadenylation
signals, and others. Such a regulatory sequence comprises all the
components required for the expression of a polynucleotide linked
thereto. In addition, a vector of the present invention preferably
comprises a selection marker. Moreover, a signal peptide required
for transferring an intracellularly expressed polypeptide into the
lumen of the endoplasmic reticulum, or the periplasm or
extracellular space when the host is a Gram negative microbe, can
also be incorporated into an expression vector by linking to a
polypeptide of interest. Such a signal peptide may comprise the 17
amino acid residues seen in naturally-occurring 65B13.
Alternatively, it can be a signal peptide derived from a
heterogeneous protein. Moreover, a linker may be added, and a start
(ATG) or stop codon (TAA, TAG or TGA) may be inserted as
necessary.
[0060] A vector of the present invention is preferably an
expression vector. An "expression vector" refers to a construct
capable of expressing a polypeptide encoded in an expression vector
in target host cells in vitro. The expression vectors of the
present invention include cloning vectors, binary vectors,
integration vectors, and such. Expression processes include
transcription of the coding sequence comprised on an expression
vector into translatable mRNA, translation of the mRNA into a
polypeptide of the present invention, and in some cases, secretion
of the expressed polypeptide into the lumen of the endoplasmic
reticulum, the periplasm, or extracellular space.
[0061] pBEST (Promega) is an example of a vector capable of
expressing polynucleotides in vitro. In addition, examples of
promoters capable of expressing polynucleotides in prokaryotic
cells such as E. coli, include P.sub.L, araB (Better et al. (1988)
Science 240: 1041-3), lacZ (Ward et al. (1989) Nature 341: 544-6;
Ward et al. (1992) FASEB J. 6: 2422-7), trp, tac and trc (fusion of
lac and trp). In addition, terminators derived from trpA, phages,
and rrnB ribosomal RNAs can also be used. Moreover, vectors to be
used in E. coli preferably have an "ori" for amplifying the vector
within a host, and a marker gene for selecting a transformed host.
The use of a drug resistance gene is preferred, which allows the
host to be distinguished by drugs such as ampicillin, tetracyclin,
kanamycin, and chloramphenicol. The pe1B signal sequence can be
used, particularly if the polypeptide is intended for secretion
into the periplasm (Lei et al. (1987) J. Bacteriol. 169: 4379).
Examples include M13 vectors, pUC vectors, pBR322, pCR-Script,
pGEX-5.times.-1 (Pharmacia), pEGFP, pBluescript (Stratagene), and
pET (Invitrogen; a preferable host for this vector is BL21
expressing the T7 polymerase). In addition, subcloning or excision
vectors can be exemplified by pGEM-T, pDIRECT and pT7, in
particular.
[0062] An example of a bacterial host other than E. coli is the
genus Bacillus, and examples of vectors include pUB110 and pc194
vectors. Specific examples include pPL608 and pKTH50 derived from
Bacillus subtilis. Vectors have also been developed for host
bacteria, for example, genus Pseudomonas such as Pseudomonas putida
and Pseudomonas cepacia, genus Brevibacterium such as
Brevibacterium lactofermentum (pAJ43 (Gene 39: 281 (1985) etc.)),
genus Corynebacterium such as Corynebacterium glutamicum (pCS 11
(Unexamined Published Japanese Patent Application No. Sho
57-183799); pCB101 (Mol. Gen. Genet. 196: 175 (1984), etc.)), genus
Streptococcus (pHV1301 (FEMS Microbiol. Lett. 26: 239 (1985)); pGK1
(Appl. Environ. Microbiol. 50: 94 (1985)), etc.), genus
Lactobacillus (pAM.beta.1 (J. Bacteriol. 137: 614 (1979), etc.)),
genus Rhodococcus such as Rhodococcus rhodochrous (J. Gen.
Microbiol. 138: 1003 (1992)), and genus Streptomyces such as
Streptomyces lividans and Streptomyces virginiae (see Genetic
Manipulation of Streptomyces: A Laboratory Manual, Hopwood et al.,
Cold Spring Harbor Laboratories (1985); pIJ486 (Mol. Gen. Genet.
203: 468-478 (1986)), pKC1064 (Gene 103: 97-9 (1991)), pUWL-KS
(Gene 165: 149-50 (1995))). See literatures such as "Basic
Microbiology Course 8--Genetic Engineering" (Kyoritsu Publishing)
for useful vectors in microbe hosts. Techniques such as the calcium
chloride method (Mandel and Higa (1970) J. Mol. Biol. 53: 158-162;
Hanahan (1983) J. Mol. Biol. 166: 557-580) and electroporation can
be employed to introduce a vector into a host.
[0063] Further, regulatory elements for expression in eukaryotic
cell hosts are exemplified by the AOX1 and GAL1 promoters for yeast
hosts. Examples of expression vectors derived from yeasts include
the Pichia Expression Kit (Invitrogen), pNV11 and SP-Q01. Vectors
that can be used in yeasts are described in detail in, for example,
Adv. Biochem. Eng. 43: 75-102 (1990) and Yeast 8: 423-88 (1992).
More specifically, vectors such as YRp, YEp, Ycp, and YIp can be
used in genus Saccharomyces such as Saccharomyces cerevisiae.
Integration vectors (such as EP537456), which allow a large number
of gene copies to be inserted, and can stably maintain the inserted
genes, are particularly useful. Other examples of vectors include 2
.mu.m vectors derived from S. cerevisiae, pKD1 vectors (J.
Bacteriol. 145: 382-90 (1981), pGK11-derived vectors, and
Kluyveromyces autonomous replication gene KARS vectors for genus
Kluyveromyces such as Kluyveromyces lactis; vectors described in
Mol. Cell. Biol. 6: 80 (1986) and pAUR224 (Takara Shuzo) for genus
Schizosaccharomyces; pSB3-derived vectors (Nucleic Acids Res. 13:
4267 (1985)) for genus Zygosaccharomyces; vectors described in
literatures such as Yeast 7: 431-43 (1991), Mol. Cell. Biol. 5:
3376 (1985) and Nucleic Acids Res. 15: 3859 (1987) for genus Pichia
such as Pichia angusta and Pichia pastoris; vectors described in
Unexamined Published Japanese Patent Application No. Hei 8-173170
or vectors using ARS derived from Candida maltosa (Agri. Biol.
Chem. 51: 1587 (1987)) for C. maltosa, C. albicans, C. tropicalis
or C. utilis; vectors described in Trends in Biotechnology 7: 283-7
(1989) for genus Aspergillus such as Aspergillus niger and A.
oryzae; and vectors using promoters derived from the extracellular
cellulase gene (Bio/technology 7: 596-603 (1989)) in genus
Trichoderma.
[0064] For hosts of mammalian cells or other animal cells, the
adenovirus late promoter (Kaufman et al. (1989) Mol. Cell. Biol. 9:
946), CAG promoter (Niwa et al. (1991) Gene 108: 193-200), CMV
immediate-early promoter (Seed and Aruffo (1987) Proc. Natl. Acad.
Sci. USA 84: 3365-9), EF1.alpha. promoter (Mizushima et al. (1990)
Nucleic Acids Res. 18: 5322; Kim et al. (1990) Gene 91: 217-23),
HSV TK promoter, SR.alpha. promoter (Takebe et al. (1988) Mol.
Cell. Biol. 8: 466), SV40 promoter (Mulligan et al. (1979) Nature
277: 108), SV40 early promoter (Genetic Engineering Vol. 3,
Williamson ed., Academic Press (1982) pp. 83-141), SV40 late
promoter (Gheysen and Fiers (1982) J. Mol. Appl. Genet. 1: 385-94),
RSV (Rous sarcoma virus)-LTR promoter (Cullen (1987) Methods
Enzymol. 152: 684-704), MMLV-LTR promoter, CMV enhancer, SV40
enhancer and globin intron, and such can be used.
[0065] Moreover, the vector preferably comprises a drug resistance
gene to allow cells to be distinguished by drugs such as neomycin
or G418. To increase the number of gene copies within cells, the
number of copies can be amplified by using methotrexate (MTX) in,
for example, a CHO host which is defective in the nucleic acid
synthesis pathway, and employing a vector such as pCHOI, which has
a DHFR gene to compensate for the defect. On the other hand, in
order to transiently express a gene, COS cells having an SV40 T
antigen gene on their chromosomes can be used as the host, and a
vector having an SV40 replication origin, such as pcD, or a vector
having a replication origin of adenovirus, bovine papilloma virus
(BPV), polyoma virus, and such can be used. Moreover, a gene
encoding aminoglycoside transferase (APH), thymidine kinase (TK),
xanthine-guanine phosphoribosyl transferase (Ecogpt), dihydrofolic
acid reductase (dhfr), or such may be included as a selection
marker for amplifying the gene copy number. Known examples of
suitable vectors are the Okayama-Berg expression vector pcDV1
(Pharmacia), pCDM8 (Nature 329: 840-2 (1987)), pRc/CMV, pcDNA1,
pcDNA3 (Invitrogen), pSPORT1 (GIBCO BRL), pSV2dhfr (Mol. Cell.
Biol. 1: 854-64 (1981)), pEF-BOS (Nucleic Acids Res. 18: 5322
(1990)), pCEP4 (Invitrogen), pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV,
pOP13, and pME18S (Mol. Cell. Biol. 8: 466-72 (1988)).
[0066] In particular, examples of vectors used to express a
polynucleotide of the present invention in animals in vivo include
adenovirus vectors such as pAdexlcw and retrovirus vectors such as
pZIPneo. A vector can be introduced into a host using methods such
as the adenovirus methods, electroporation (Cytotechnology 3: 133
(1990)), cationic liposome methods (Cationic Liposome DOTAP
(Boehringer Mannheim), etc.), introduction using positively charged
polymers, electrostatic type liposome methods, internal type
liposome methods, particle gun methods, liposome methods,
lipofection (Proc. Natl. Acad. Sci. USA 84: 7413 (1987)), calcium
phosphate methods (Unexamined Published Japanese Patent Application
No. Hei 2-227075), receptor-mediated gene introduction methods,
retrovirus methods, DEAE dextran methods, virus-liposome methods
(Experimental Medicine Supplement, "Basic Technology of Gene
Therapy", Yodosha (1997); Experimental Medicine Supplement,
"Experimental Method of Gene Introduction and Expression Analysis",
Yodosha (1997); J. Clin. Invest. 93: 1458-64 (1994); Am. J.
Physiol. 271: R1212-20 (1996); Molecular Medicine 30: 1440-8
(1993); Experimental Medicine 12: 1822-6 (1994); Protein, Nucleic
acid, and Enzyme 42: 1806-13 (1997); Circulation 92 (Suppl. II):
479-82 (1995)), and naked-DNA direct introduction methods. Vectors
generated using virus vectors derived from viruses other than
adenoviruses and retroviruses, such as adeno-associated virus,
Sindbis virus, Sendai virus, Togavirus, Paramyxovirus, poxvirus,
poliovirus, herpes virus, lentivirus and vaccinia virus, can also
be used. Administration into the living body may be carried out
using ex vivo or in vivo methods.
[0067] In addition, insect expression systems are also known as
systems for expressing heterogeneous polypeptides. For example,
exogenous genes can be expressed in Spodoptera frugiperda cells or
Trichoplusia larvae cells, using the Autographa california
nucleopolyhedrosis virus (AcNPV) as a vector. Here, an exogenous
gene of interest is cloned into the non-essential region of a
virus. For example, it may be linked to a region under the control
of a polyhedrin promoter. In this case, the polyhedrin gene is
deactivated, a recombinant virus lacking the coat protein is
produced, and a polypeptide of interest is expressed in cells of
Spodoptera frugiperda, Trichoplusia larvae, or such, that have been
infected with the virus (Smith (1983) J. Virol. 46: 584; Engelhard
(1994) Proc. Natl. Acad. Sci. USA 91: 3224-7). Other known examples
of insect cell-derived expression vectors include the Bac-to-BAC
Baculovirus Expression System (Bigco BRL) and pBacPAK8.
[0068] When plant cells are used as a host, for example, vectors
that use the 35S promoter of cauliflower mosaic virus can be used.
Known methods of introducing a vector into plant cells include the
PEG, electroporation, Agrobacterium methods, and particle gun
methods.
[0069] Insertion of a DNA into a vector can be carried out in a
ligase reaction using restriction enzyme sites (Current Protocols
in Molecular Biology, John Wiley & Sons (1987) Section
11.4-11.11; Molecular Cloning, A Laboratory Manual 2.sup.nd ed.,
Cold Spring Harbor Press (1989) Section 5.61-5.63).
<Hosts>
[0070] The present invention provides hosts that comprise a
polynucleotide or vector of the present invention. An in vitro or
in vivo production system may be employed for the production of a
polypeptide of the present invention. Hosts of the present
invention include archaebacterial, bacterial, fungal, plant,
insect, fish, amphibian, reptilian, avian, and mammalian
prokaryotic and eukaryotic cells. A host of the present invention
comprises in its cells a polynucleotide that encodes a polypeptide
of the present invention. As long as the polynucleotide does not
exist at a naturally occurring position in the genome of a host
cell, the polynucleotide may be regulated by its own promoter,
incorporated into the host genome, or maintained as an
extrachromosomal structure.
[0071] Examples of bacterial hosts include Gram positive and Gram
negative bacteria belonging to the genus Escherichia,
Streptococcus, Staphylococcus, Serratia or Bacillus, such as E.
coli (JM109, DH5.alpha., HB101 and XL1Blue), Serratia marcescens,
and Bacillus subtilis.
[0072] Examples of a eukaryotic host include fungal cells such as
yeasts, higher plants (Nicotiana tabacum derived cells), insects
(Drosophila S2, Spodoptera Sf9, Sf21, Tn5), fish, amphibians
(Xenopus oocytes (Valle et al. (1981) Nature 291: 358-40),
reptiles, birds, and mammals (CHO (J. Exp. Med. 108: 945 (1995).
Among them, DHFR gene-deficient dhfr-CHO (Proc. Natl. Acad. Sci.
USA 77: 4216-20 (1980) and CHO K-1 (Proc. Natl. Acad. Sci. USA 60:
1275 (1968)), COS, Hela, C127, 3T3, BHK, HEK293 and Bowes melanoma
cells), myeloma, Vero, Namalwa, Namalwa KJM-1 and HBT5637
(Unexamined Published Japanese Patent Application No. Sho 63-299),
and plants (potato, tobacco, corn, rice, rape, soybean, tomato,
wheat, barley, rye, alfalfa, and hemp), are included. In addition
to Saccharomyces cerevisiae belonging to the genus Saccharomyces,
and yeasts belonging to the genus Pichia, expression systems that
use fungi as a host, such as the cells of Aspergillus niger
belonging to the mold Aspergillus, are also known.
[0073] Introduction of a vector into host cells can be carried out
using methods such as the electroporation (Chu et al. (1987)
Nucleic Acids Res. 15: 1311-26), cationic liposome methods,
electric pulse terebration (Current Protocols in Molecular Biology,
John Wiley & Sons (1987) Sections 9.1 to 9.9), direct injection
using a microscopic glass tube, microinjection, lipofection
(Derijard (1994) Cell 7: 1025-37; Lamb (1993) Nature Genetics 5:
22-30; Rabindran et al. (1993) Science 259: 230-4), lipofectamine
method (GIBCO-BRL), calcium phosphate method (Chen and Okayama
(1987) Mol. Cell. Biol. 7: 2745-52), DEAE dextran method (Lopata et
al. (1984) Nucleic Acids Res. 12: 5707-17; Sussman and Milman
(1985) Mol. Cell. Biol. 4: 1642-3) and FuGene6 reagent
(Boehringer-Mannheim).
<Polypeptides and Polypeptide Fragments>
[0074] A "polypeptide" of the present invention refers to a peptide
polymer encoded by a polynucleotide of the present invention.
Preferred examples include proteins having the amino acid sequence
described in SEQ ID NOs: 3 or 4. The polypeptides of the present
invention may comprise naturally occurring or modified amino acid
residues. Examples of amino acid residue modifications include
acylation, acetylation, amidation, arginylation, GPI anchor
formation, crosslinking, .gamma.-carboxylation, cyclization,
covalent crosslink formation, glycosylation, oxidation, covalent
bonding of a lipid or fat derivative, cystine formation, disulfide
bond formation, selenoylation, demethylation, protein fragmentation
treatment, covalent bonding of a nucleotide or nucleotide
derivative, hydroxylation, pyroglutamate formation, covalent
bonding of a flavin, prenylation, covalent bonding with a heme
portion, covalent bonding of phosphatidyl inositol, formylation,
myristoylation, methylation, ubiquitination, iodination,
racemization, ADP-ribosylation, sulfation and phosphorylation.
Moreover, the polypeptides of the present invention include
precursors containing a signal peptide portion, mature proteins
lacking a signal peptide portion, and fusion proteins modified with
other peptide sequences. Peptide sequences to be added to a
polypeptide of the present invention can be selected from sequences
that facilitate protein purification using, for example,
pcDNA3.1/Myc-His vector (Invitrogen), or those that confer
stability in recombinant protein production. Examples of such
sequences are influenza agglutinin (HA), glutathione S transferase
(GST), substance P, multiple histidine tag (such as 6.times.His and
10.times.His), protein C fragment, maltose-binding protein (MBP),
immunoglobulin constant region, .alpha.-tubulin fragment,
.beta.-galactosidase, B-tag, c-myc fragment, E-tag (epitope on a
monoclonal phage), FLAG (Hopp et al. (1988) Bio/Technol. 6:
1204-10), 1ck tag, p18 HIV fragment, HSV-tag (human simple Herpes
virus glycoprotein), SV40T antigen fragment, T7-tag (T7 gene 10
protein), and VSV-GP fragment (vesicular stomatitis virus
glycoprotein).
[0075] Moreover, the present invention also provides fragments of
the polypeptides of the present invention. A polypeptide fragment
of the present invention is identical to a portion of a polypeptide
of the present invention, and comprises at least eight amino acid
residues or more (for example, 8, 10, 12 or 15 amino acid residues
or more). A particularly preferable fragment can be exemplified by
a polypeptide fragment lacking an amino terminus, carboxyl
terminus, and transmembrane domain. The polypeptide fragments of
the present invention include fragments containing an .alpha.-helix
and .alpha.-helix forming region, .alpha.-amphipathic region,
.beta.-sheet and .beta.-sheet forming region, .beta.-amphipathic
region, substrate binding region, high antigen index region, coil
and coil forming region, hydrophilic region, hydrophobic region,
turn and turn forming region, and surface forming region. A
polypeptide fragment of the present invention may be any fragment,
provided that it has the antigenicity of a polypeptide of the
present invention. The antigen-determining site of a polypeptide
can be predicted using methods for analyzing protein hydrophobicity
and hydrophilicity of an amino acid sequence (Kyte-Doolittle (1982)
J. Mol. Biol. 157: 105-22), or methods of secondary structure
analysis (Chou-Fasman (1978) Ann. Rev. Biochem. 47: 251-76), and
can be confirmed using a computer program (Anal. Biochem. 151:
540-6 (1985), or the PEPSCAN method in which a short peptide is
synthesized followed by confirmation of its antigenicity (Published
Japanese Translation of International Publication No. Sho
60-500684).
[0076] The polypeptides or polypeptide fragments of the present
invention can be produced by using known genetic recombination
techniques or chemical synthesis. When producing a polypeptide or
polypeptide fragment of the present invention using genetic
recombination techniques, the produced protein may or may not be
subjected to glycosylation depending on the type of host selected,
and may differ in molecular weight, isoelectric point or such.
Normally when a polypeptide is expressed using a prokaryotic cell
such as E. coli as the host, the resulting polypeptide is produced
in a form that has a methionine residue attached to the N terminus
of the original polypeptide. Polypeptides having different
structures due to such differences in host are also included in the
polypeptides of the present invention.
<Polypeptide Production>
[0077] For in vitro polypeptide production, polypeptides can be
produced in an in vitro cell-free system using methods such as in
vitro translation (Dasso and Jackson (1989) Nucleic Acids Res. 17:
3129-44). In contrast, when producing polypeptides using cells, a
suitable cell host is first selected from those mentioned above,
and then the cells are transformed with a DNA of interest.
Subsequently, the transformed cells can be cultured to obtain a
polypeptide of interest. Culturing is carried out using known
methods that are appropriate for the cell host selected. For
example, when animal cells are selected, culturing can be carried
out at a pH of about 6 to 8 and a temperature of 30.degree. C. to
40.degree. C. for about 15 to 200 hours, using a medium such as
DMEM (Virology 8: 396 (1959)), MEM (Science 122: 501 (1952)),
RPMI1640 (J. Am. Med. Assoc. 199: 519 (1967)), 199 (Proc. Soc.
Biol. Med. 73: 1 (1950)) or IMDM, and adding serum such as fetal
calf serum (FCS), as necessary. In addition, the medium may be
replaced, aerated, or stirred, during the course of culturing, as
necessary.
[0078] On the other hand, in order to establish an in vivo
polypeptide production system, a DNA of interest is introduced into
an animal or plant, and the polypeptide is produced in vivo.
Examples of known animal systems (Lubon (1998) Biotechnol. Annu.
Rev. 4: 1-54) include mammals such as goats, pigs, sheep, mice, and
cows, and insects such as silkworms (Susumu (1985) Nature 315:
592-4). In addition, transgenic animals can also be used in
mammalian systems.
[0079] For example, when secreting a polypeptide of interest in
goat milk, a DNA that encodes the polypeptide is linked to a DNA
that encodes a protein such as .beta.-casein, and a fusion protein
of the polypeptide of interest is specifically expressed in milk.
Next, the DNA that encodes the fusion protein is introduced into a
goat embryo. The embryo harboring this DNA is then transferred back
into the uterus of a female goat. The transgenic goats or their
offspring born from this female goat secretes the polypeptide of
interest in their milk. Hormones may also be administered to
increase the amount of milk, as necessary (Ebert et al. (1994)
Bio/Technology 12: 699-702).
[0080] Transgenic plant polypeptide production systems using plants
such as tobacco are known. First, a DNA that encodes a polypeptide
of interest is incorporated into a plant expression vector such as
pMON530, and this vector is then introduced into a bacterium such
as Agrobacterium tumefaciens. A bacterium harboring this DNA is
then used to infect plants such as Nicotina tabacum, and the
polypeptide of interest can be isolated from the leaves of the
resulting transgenic plant upon regeneration of the plant body
(Julian et al. (1994) Eur. J. Immunol. 24: 131-8). Examples of
other established methods include methods in which a DNA is
introduced into a protoplast using PEG followed by regeneration of
the plant body (Gene Transfer to Plants, Potrykus and Spangenberg
ed. (1995) pp. 66-74; suitable for Indian rice varieties), methods
in which a DNA is introduced into a protoplast by electric pulse
followed by regeneration of the plant body (Toki et al. (1992)
Plant Physiol. 100: 1503-7; suitable for Japanese rice varieties),
methods in which a DNA is directly introduced into plant cells
using the particle gun method followed by regeneration of the plant
body (Christou et al. (1991) Bio/Technology 9: 957-62), and methods
in which a DNA is introduced into cells via Agrobacterium followed
by regeneration of the plant body (Hiei et al. (1994) Plant J. 6:
271-82). See Toki et al. (1995) Plant Physiol. 100: 1503-7 for
methods of plant regeneration.
[0081] Once a transgenic plant is obtained, a plant host that
produces a polypeptide of the present invention can be propagated
in the same manner, using the seeds, fruits, tubers, root tubers,
stocks, cuttings, calluses, or protoplasts of the plant.
[0082] Normally, a polypeptide of the present invention produced by
gene recombination techniques can be recovered from the medium if
the polypeptide is secreted outside of a cell, or from the body
fluid of a transgenic organism. When a polypeptide is produced
inside of a cell, the cells are dissolved and the polypeptide is
recovered from the dissolved product. The polypeptide of interest
is then purified by suitably combining known methods of protein
purification such as salting out, distillation, various types of
chromatography, gel electrophoresis, gel filtration,
ultrafiltration, recrystallization, acid extraction, dialysis,
immunoprecipitation, solvent precipitation, solvent extraction, and
ammonium sulfate or ethanol precipitation. Examples of
chromatographies include ion exchange chromatography, such as anion
or cation exchange chromatography, affinity chromatography,
reversed-phase chromatography, adsorption chromatography, gel
filtration chromatography, hydrophobic chromatography,
hydroxyapatite chromatography, phosphocellulose chromatography, and
lectin chromatography (Strategies for Protein Purification and
Characterization: A Laboratory Course Manual, Marshak et al. ed.,
Cold Spring Harbor Laboratory Press (1996)). Chromatography can be
carried out using a liquid phase chromatography such as HPLC or
FPLC.
[0083] In addition, naturally-occurring polypeptides can also be
purified and obtained. For example, polypeptides can be purified by
affinity chromatography using antibodies against the polypeptides
of the present invention to be described below (Current Protocols
in Molecular Biology, John Wiley & Sons (1987) Section
16.1-16.19). In addition, purification can also be carried out
using a glutathione column for GST-fusion proteins, or a nickel
column for histidine-tagged fusion proteins. When producing a
polypeptide of the present invention in the form of a fusion
protein, unwanted portions can be cleaved using thrombin or factor
Xa and such, following purification, as necessary. Moreover, the
resulting polypeptide can also be modified using enzymes such as
chymotrypsin, glucosidase, trypsin, protein kinase, and lysyl
endopeptidase, as necessary.
[0084] In addition to the aforementioned synthesis and genetic
engineering techniques, a polypeptide fragment of the present
invention can also be produced by cleaving a polypeptide of the
present invention, using suitable enzymes such as peptidase.
<Antibodies>
[0085] The present invention also provides antibodies against the
polypeptides or polypeptide fragments of the present invention.
Antibodies of the present invention also include polyclonal
antibodies, monoclonal antibodies, chimeric antibodies,
single-chain antibodies (scFV) (Huston et al. (1988) Proc. Natl.
Acad. Sci. USA 85: 5879-83; The Pharmacology of Monoclonal
Antibody, vol. 113, Rosenburg and Moore ed., Springer Verlag (1994)
pp. 269-315), humanized antibodies, multispecific antibodies
(LeDoussal et al. (1992) Int. J. Cancer Suppl. 7: 58-62; Paulus
(1985) Behring Inst. Mitt. 78: 118-32; Millstein and Cuello (1983)
Nature 305: 537-9; Zimmermann (1986) Rev. Physiol. Biochem.
Pharmacol. 105: 176-260; Van Dijk et al. (1989) Int. J. Cancer 43:
944-9), and antibody fragments such as Fab, Fab', F(ab')2, Fc, and
Fv. Moreover, an antibody of the present invention may also be
modified by PEG and such, as necessary. An antibody of the present
invention may also be produced in the form of a fusion protein with
.beta.-galactosidase, maltose-binding protein, GST, green
fluorescent protein (GFP), or such, to allow detection without the
use of a secondary antibody. In addition, an antibody may be
modified by labeling with biotin or such to allow recovery using
avidin, streptoavidin, or such.
[0086] An antibody of the present invention can be produced using a
polypeptide of the present invention, a fragment thereof, or cells
in which a polypeptide or polypeptide fragment of the present
invention is expressed, as a sensitized antigen. In addition, a
short polypeptide of the present invention, or a fragment thereof,
may also be used as an immunogen by coupling to a carrier such as
bovine serum albumin, Keyhole-limpet hemocyanin, and ovalbumin. In
addition, a polypeptide of the present invention, or a fragment
thereof, may be used in combination with a known adjuvant such as
aluminum adjuvant, Freund's complete (or incomplete) adjuvant, or
pertussis adjuvant, to enhance the immune response to an
antigen.
[0087] Polyclonal antibodies can be obtained from, for example, the
serum of an immunized animal after immunizing a mammal with a
polypeptide of the present invention, or a fragment thereof,
coupled to a desired adjuvant. Although there are no particular
limitations on the mammals used, typical examples include rodents,
lagomorphs, and primates. Specific examples include rodents such as
mice, rats and hamsters, lagomorphs such as rabbits, and primates
such as monkeys, including cynomolgus monkeys, rhesus monkeys,
baboons and chimpanzees. Animal immunization is carried out by
suitably diluting and suspending a sensitized antigen in
phosphate-buffered saline (PBS) or physiological saline, mixing
with an adjuvant as necessary until emulsified, and injecting into
an animal intraperitoneally or subcutaneously. The sensitized
antigen mixed with Freund's incomplete adjuvant is preferably
administered several times, every 4 to 21 days. Antibody production
can be confirmed by measuring the level of an antibody of interest
in the serum using conventional methods. Finally, the serum itself
may be used as a polyclonal antibody, or it may be further
purified. See, for example, "Current Protocols in Molecular
Biology" (John Wiley & Sons (1987) Sections 11.12-11.13), for
specific methods.
[0088] A monoclonal antibody can be produced by removing the spleen
from an animal immunized in the manner described above, separating
immunocytes from the spleen, and fusing with a suitable myeloma
cell using polyethylene glycol (PEG) or such to establish
hybridomas. Cell fusion can be carried out according to the
Milstein method (Galfre and Milstein (1981) Methods Enzymol. 73:
3-46). Here, suitable myeloma cells are exemplified particularly by
cells that allow chemical selection of fused cells. When using such
myeloma cells, fused hybridomas are selected by culturing in a
culture medium (HAT culture medium) that contains hypoxanthine,
aminopterin and thymidine, which destroy cells other than the fused
cells. Next, a clone that produces an antibody against a
polypeptide of the present invention, or a fragment thereof, is
selected from the established hybridomas. Subsequently, the
selected clone is introduced into the abdominal cavity of a mouse
or such, and ascites is collected to obtain a monoclonal antibody.
See, in addition, "Current Protocols in Molecular Biology" (John
Wiley & Sons (1987) Section 11.4-11.11), for information on
specific methods.
[0089] Hybridomas can also be obtained by first sensitizing human
lymphocytes that have been infected by EB virus with an immunogen
in vitro, and fusing the sensitized lymphocytes with human myeloma
cells (such as U266) to obtain hybridomas that produce human
antibodies (Unexamined Published Japanese Patent Application No.
Sho 63-17688). In addition, human antibodies can also be obtained
by using antibody-producing cells generated by sensitizing a
transgenic animal with a human antibody gene repertoire
(WO92/03918; WO93-02227; WO94/02602; WO94/25585; WO96/33735;
WO96/34096; Mendez et al. (1997) Nat. Genet. 15: 146-156, etc.).
Methods that do not use hybridomas can be exemplified by a method
in which a cancer gene is introduced to immortalize immunocytes
such as antibody producing lymphocytes.
[0090] In addition, antibodies can also be produced by genetic
recombination techniques (see Borrebaeck and Larrick (1990)
Therapeutic Monoclonal Antibodies, MacMillan Publishers Ltd., UK).
First, a gene that encodes an antibody is cloned from hybridomas or
antibody-producing cells (such as sensitized lymphocytes). The
resulting gene is then inserted into a suitable vector, the vector
is introduced into a host, and the host is then cultured to produce
the antibody. This type of recombinant antibody is also included in
the antibodies of the present invention. Typical examples of
recombinant antibodies include chimeric antibodies comprising a
non-human antibody-derived variable region and a human
antibody-derived constant region, and humanized antibodies
comprising a non-human-derived antibody complementarity determining
region (CDR), human antibody-derived framework region (FR), and
human antibody constant region (Jones et al. (1986) Nature 321:
522-5; Reichmann et al. (1988) Nature 332: 323-9; Presta (1992)
Curr. Op. Struct. Biol. 2: 593-6; Methods Enzymol. 203: 99-121
(1991)).
[0091] Antibody fragments of the present invention can be produced
by treating the aforementioned polyclonal or monoclonal antibodies
with enzymes such as papain or pepsin. Alternatively, an antibody
fragment can be produced by genetic engineering techniques using a
gene that encodes an antibody fragment (see Co et al., (1994) J.
Immunol. 152: 2968-76; Better and Horwitz (1989) Methods Enzymol.
178: 476-96; Pluckthun and Skerra (1989) Methods Enzymol. 178:
497-515; Lamoyi (1986) Methods Enzymol. 121: 652-63; Rousseaux et
al. (1986) 121: 663-9; Bird and Walker (1991) Trends Biotechnol. 9:
132-7).
[0092] The multispecific antibodies of the present invention
include bispecific antibodies (BsAb), diabodies (Db), and such.
Multispecific antibodies can be produced by methods such as (1)
chemically coupling antibodies having different specificities with
different types of bifunctional linkers (Paulus (1985) Behring
Inst. Mill. 78: 118-32), (2) fusing hybridomas that secrete
different monoclonal antibodies (Millstein and Cuello (1983) Nature
305: 537-9), or (3) transfecting eukaryotic cell expression
systems, such as mouse myeloma cells, with a light chain gene and a
heavy chain gene of different polyclonal antibodies (four types of
DNA), followed by the isolation of a bispecific monovalent portion
(Zimmermann (1986) Rev. Physio. Biochem. Pharmacol. 105: 176-260;
Van Dijk et al. (1989) Int. J. Cancer 43: 944-9). On the other
hand, diabodies are dimer antibody fragments comprising two
bivalent polypeptide chains that can be constructed by gene fusion.
These can be produced using known methods (see Holliger et al.
(1993) Proc. Natl. Acad. Sci. USA 90: 6444-8; EP404097;
WO93/11161).
[0093] Recovery and purification of antibodies and antibody
fragments can be carried out using Protein A and Protein G, or
according to the protein purification techniques described in
detail under "Production of Polypeptides" (Antibodies: A Laboratory
Manual, Ed Harlow and David Lane, Cold Spring Harbor Laboratory
(1988)). For example, when using Protein A to purify an antibody of
the present invention, known Protein A columns such as Hyper D,
POROS or Sepharose F.F. (Pharmacia) can be used. The concentration
of the resulting antibody can be determined by measuring the
absorbance or by enzyme linked immunoadsorbent assay (ELISA).
[0094] Antigen binding activity of an antibody can be determined by
absorbance measurement, or by using fluorescent antibody methods,
enzyme immunoassay (EIA) methods, radioimmunoassay (RIA) methods,
or ELISA. When ELISA is used, an antibody of the present invention
is first immobilized onto a support such as a plate. A polypeptide
of the present invention is added, and then a sample containing the
antibody of interest is added. Here, samples containing an antibody
of interest include, for example, culture supernatants of
antibody-producing cells, purified antibodies, and such. Next, a
secondary antibody that recognizes an antibody of the present
invention is added, followed by the incubation of the plate.
Subsequently, the plate is washed and the label attached to the
secondary antibody is detected. Namely, if a secondary antibody is
labeled with alkaline phosphatase, the antigen binding activity can
be determined by adding an enzyme substrate such as p-nitrophenyl
phosphate, and measuring the absorbance. In addition, a
commercially available system such as BIAcore (Pharmacia) can also
be used to evaluate antibody activities.
[0095] The antibodies of the present invention can be used to
purify polypeptides of the present invention, or fragments thereof.
In addition, the antibodies of this invention can also be used to
obtain dopaminergic neuron precursor cells that can be suitably
used in cell transplant therapy for diseases such as Parkinson's
disease.
<Selection of Dopaminergic Neurons>
[0096] The present invention provides a method of selectively
obtaining homogenous populations of dopaminergic neuron precursor
cells immediately after the cell cycle exit. More specifically,
cells that express a polypeptide of the present invention, namely,
immediate postmitotic dopaminergic neuron precursor cells, can be
obtained by contacting an antibody against a 65B13 polypeptide of
the present invention with a cell sample containing potential
dopaminergic neuron precursor cells, and then selecting those cells
that have bound to the antibody (see FIGS. 12 through 14). The
antibody may also be immobilized on a suitable support prior to
cellular contact. Alternatively, cells that bind to the antibody
can be selectively recovered, by contacting cells with an antibody
and allowing them to bind, and purifying by affinity chromatography
for the antibody. For example, if an antibody of the present
invention is conjugated to biotin, it can be purified on a plate or
column bound with avidin or streptoavidin.
[0097] In addition, 65B13 has an adhesion molecule-like structure
with an Ig domain (see FIG. 6) and when it is expressed in cultured
cells, cells that express 65B13 adhere to each other, but not to
those that do not express 65B13. Therefore, the 65B13-mediated
adhesion is considered to involve homophilic binding. Based on such
properties of the 65B13 polypeptide, dopaminergic neuron precursor
cells can also be selected by utilizing the 65B13 polypeptide,
particularly the extracellular portion thereof. For example,
dopaminergic neuron precursor cells can be obtained by fixing the
extracellular portion of the 65B13 polypeptide on a suitable
support, and then contacting the support with cells. Thus, the
present invention provides methods of selecting dopaminergic neuron
precursor cells, wherein the methods comprise the step of
contacting a peptide comprising at least the extracellular portion
of a polypeptide of the present invention with a cell sample
contacting dopaminergic neuron precursor cells.
[0098] In the present invention, immediate postmitotic dopaminergic
neuron precursor cells can be efficiently separated by flow
cytometry using an anti-65B13 antibody (Example 4, FIG. 14).
[0099] In addition, dopaminergic neuron precursor cells can also be
selected using a promoter for 65B13 (see, for example, Unexamined
Published Japanese Patent Application No. 2002-51775). For example,
a vector harboring a construct that comprises a gene encoding a
detection marker, such as GFP, linked to a promoter region obtained
from analyzing the 65B13 expression regulatory regions to be
described later, can be transfected into cells. In addition, a gene
encoding a marker can also be knocked in at the 65B13 gene locus.
In either case, specific cells can be selected by detecting the
expression of a marker gene specific for dopaminergic neuron
precursor cells.
[0100] The cell sample used here preferably comprises cells of the
ventral midbrain region or cell culture containing in vitro
differentiated dopaminergic neurons. In vitro differentiation of
dopaminergic neurons can be carried out by known methods using
cells such as known ES cells, bone marrow interstitial cells,
immortalized neuron-derived cell lines (Published Japanese
Translation of International Publication No. Hei 8-509215;
Published Japanese Translation of International Publication No. Hei
11-506930; Published Japanese Translation of International
Publication No. 2002-522070), or primordial neuron cells (Published
Japanese Translation of International Publication No. Hei
11-509729), as the starting material. Normally, dopaminergic
neurons can be differentiated by co-culturing a tissue obtained
from a dopaminergic neuron region of the brain, with a
sustentacular cell layer derived from neural tissues. Moreover,
methods are also known for deriving dopaminergic cells from neural
tissues that normally do not produce dopamine, such as the striatum
and cortex (Published Japanese Translation of International
Publication No. Hei 10-509319). In addition, culturing under
hypoxic conditions has been reported to produce cells containing a
greater number of dopaminergic neurons (Published Japanese
Translation of International Publication No. 2002-530068). A cell
sample used in the selection of dopaminergic neuron precursor cells
of the present invention may be a cell population isolated or
cultured by any method.
[0101] In addition, it is necessary that a support used in
immobilizing an antibody or a polypeptide of the present invention
be safe to cells. Examples of such a support include synthetic or
naturally-occurring organic polymer compounds, inorganic materials
such as glass beads, silica gel, alumina, and activated charcoal,
and those that have their surfaces coated with a polysaccharide or
synthetic polymer. There are no particular limitations on the form
of the support, examples of which include films, fibers, granules,
hollow fibers, non-woven fabric, porous supports, or honeycombed
supports, and the contact surface area can be controlled by
changing its thickness, surface area, width, length, shape, and
size in various ways.
<Dopaminergic Neuron Precursor Cells>
[0102] Since cells obtained in this manner are postmitotic neuron
precursor cells, they are preferable in transplant therapy for
neurodegenerative diseases, such as Parkinson's disease, in terms
of their safety, survival rate, and network formation ability,
compared to conventional mixed cell populations or dopaminergic
neurons carrying an exogenous gene. Moreover, since cells (or cell
populations) of the present invention obtained according to the
methods of this invention are immediate postmitotic precursor
cells, they can also be differentiated into a suitable stage by
selecting in vitro conditions such as media, and are preferable
materials for various types of neural transplant therapy. When
neuron precursor cells obtained using the methods of the present
invention are used in transplants, preferably 1.times.10.sup.3 to
1.times.10.sup.6 cells, and more preferably 5.times.10.sup.4 to
6.times.10.sup.4 cells, are transplanted. The primary method is
stereotaxic surgery in which a cell suspension is transplanted into
the brain. In addition, cells may also be transplanted by
microsurgery. See, Backlund et al. (Backlund et al. (1985) J.
Neurosurg. 62: 169-73), Lindvall et al. (Lindvall et al. (1987)
Ann. Neurol. 22: 457-68) or Madrazo et al. (Madrazo et al. (1987)
New Engl. J. Med. 316: 831-4), for methods of transplanting neuron
tissues.
[0103] Moreover, the cells of the present invention can also be
used to isolate genes specific to dopaminergic neuron precursor
cells, and genes specific to each stage of the maturation from
precursor cells into dopaminergic neurons. They can also be used
for searching therapeutic targets for Parkinson's disease,
elucidating the maturation process of dopaminergic neurons, and in
screenings using maturation as an indicator.
<Comparison of Gene Expression Levels>
[0104] Postmitotic dopaminergic neuron precursor cells, which were
obtained using an antibody of the present invention can be used as
a material to isolate genes specifically expressed in these cells.
They can also be used to investigate and isolate genes specifically
expressed in cells that have differentiated, induced, or
proliferated from the dopaminergic neuron precursor cells of the
present invention. In addition, they can also be used to
investigate genes required for in vivo differentiation of
dopaminergic neurons, by investigating genes that have different
expression levels in cells that have differentiated, induced, or
proliferated from the original precursor cells. Since such genes
are potential candidates for treating diseases caused by defects in
dopaminergic neurons, their determination and isolation are
extremely useful.
[0105] Comparison of gene expression levels in dopaminergic neuron
precursor cells of the present invention with those of cells that
have differentiated, induced, or proliferated therefrom, or other
cells; or comparison of gene expression levels of the
differentiated, induced, or proliferated cells with those of other
cells, can be done by commonly used methods, such as cell in situ
hybridization, Northern blot hybridization, RNA dot blot
hybridization, reverse transcription PCR, RNase protection assay,
DNA microarray hybridization, serial analysis of gene expression
(SAGE) (Velculescu et al. (1995) Science 270: 484-487), subtractive
hybridization, and representation difference analysis (RDA)
(Lisitsyn (1995) Trends Genet. 11: 303-307).
[0106] For cellular in situ hybridization, locations where RNA
processing, transport, and localization into the cytoplasm occur in
individual cells can be investigated, by hybridizing total RNA or
poly A.sup.+ RNA prepared from cells with a labeling probe specific
to a given RNA sequence. In addition, RNA size can be determined by
size fraction using gel electrophoresis. Moreover, RNA
transcription products can be visualized in situ by using
quantitative fluorescent in situ hybridization (FISH) and a digital
imaging microscope (Femino et al. (1998) Science 280: 585-90),
which are applicable to the present invention.
[0107] When using reverse transcription PCR for gene expression
analysis, the expression of a specific gene can be roughly
quantified. Various isoforms of a single RNA transcription product
can be also be detected and analyzed using the present method. For
reverse transcription PCR, when the reaction is carried out using
exon-specific primers, and amplification products other than the
predicted product are detected, mRNA isoforms produced by
alternative splicing can be identified by analyzing these products.
See, for example, the method described in Pykett et al. (1994) Hum.
Mol. Genet. 3: 559-64, for details. When a quick and rough analysis
of expression pattern is demanded, the present method which uses
the PCR of the present invention is particularly preferred, in
terms of its high speed, high sensitivity, and simplicity.
[0108] The efficiency of gene expression screening can be improved
by using a DNA chip. Here, a DNA chip refers to a miniature array,
in which oligonucleotides, DNA clones, or such, are immobilized at
a high density on a support surface such as glass. For example, in
order to carry out multiple expression screening, cDNA clones for
each gene of interest, or oligonucleotides specific to each gene,
are immobilized on a chip to produce a microarray. Next, RNAs are
prepared from dopamine-specific neuron precursor cells of the
present invention, or cells differentiated, induced, or
proliferated therefrom, and treated with reverse transcriptase to
yield cDNAs. Next, the resulting cDNA sample is labeled with
fluorescent tags or other tags, and then hybridized to the
microarray. As a result, genes that are actively expressed in the
cells have a higher percentage of the total labeled cDNA, while
genes that are not significantly expressed have a lower percentage.
Namely, the fluorescent signal intensity which represents
hybridization between a labeled cDNA and a cDNA clone or an
oligonucleotide on the chip, reflects the expression level of each
sequence in the labeled cDNA, and thereby enables the
quantification of gene expression.
[0109] In addition, multiple genes in dopaminergic neuron precursor
cells of the present invention, or cells differentiated, induced,
or proliferated therefrom, can be simultaneously analyzed by mRNA
differential display, which involves reverse transcription PCR
using degenerate PCR primers.
[0110] First, a modified oligo dT primer is prepared, in which one
or two nucleotides at the 3' terminus in the poly A tail of a given
mRNA have been altered. Then, a reverse transcription reaction is
carried out using the total RNAs isolated from the precursor cells
of the present invention, cells differentiated or proliferated
therefrom, or control cells to be used for expression comparison
(Liang et al. (1993) Nucleic Acids Res. 21: 3269-3275). If the
altered nucleotide is a "G", then mRNA having a "C" immediately
before the poly A tail can be selectively amplified. If the altered
nucleotides are "CA", then mRNA having "TG" immediately before the
poly A tail can be selectively amplified. Next, an arbitrary
nucleotide sequence of about 10 nucleotides in length is prepared
for use as a second primer, and a PCR amplification reaction is
carried out using the modified oligo dT primer and this second
primer. The amplification product is subjected to size
fractionation by electrophoresis using a long polyacrylamide gel.
By using such a method, cDNA derived from mRNA specifically
expressed in either the cells of the present invention or the
control cells can be detected as a band only present in the either
sample that has been electrophoresed. This method can also be used
to analyze expression of unidentified genes.
[0111] SAGE analysis does not require a special device for
detection, and is one of the preferable analytical methods for
simultaneously detecting the expression of a large number of
transcription products. First, poly A.sup.+ RNA is extracted from
the dopaminergic neuron precursor cells of the present invention,
or cells differentiated, induced, or proliferated therefrom, using
standard methods. Next, the RNA is converted into cDNA using a
biotinylated oligo (dT) primer, and then treated with a four-base
recognizing restriction enzyme (Anchoring Enzyme: AE). Here, the
AE-treated fragments contain a biotin group at their 3' terminus.
Next, the AE-treated fragments are incubated with streptoavidin for
binding. The bound cDNA is divided into two fractions, and each
fraction is then linked to a different double-stranded
oligonucleotide adapter (linker) A or B. These linkers are composed
of: (1) a protruding single strand portion having a sequence
complementary to the sequence of the protruding portion formed by
the action of the anchoring enzyme, (2) a 5' nucleotide recognizing
sequence of the IIS-type restriction enzyme (cleaves at a
predetermined location no more than 20 bp away from the recognition
site) serving as a tagging enzyme (TE), and (3) an additional
sequence of sufficient length for constructing a PCR-specific
primer. Here, the linker-linked cDNA is cleaved using the tagging
enzyme, and only the linker-linked cDNA sequence portion remains,
which is present in the form of a short-strand sequence tag. Next,
pools of short-strand sequence tags from the two different types of
linkers are linked to each other, followed by PCR amplification
using primers specific to linkers A and B. As a result, the
amplification product is obtained as a mixture comprising myriad
sequences of two adjacent sequence tags (ditags) bound to linkers A
and B. The amplification product is treated with the anchoring
enzyme, and the free ditag portions are linked into strands in a
standard linkage reaction. The amplification product is then
cloned. Determination of the clone's nucleotide sequence can be
used to obtain a read-out of consecutive ditags of constant length.
The presence of mRNA corresponding to each tag can then be
identified once from the determination of the clone's nucleotide
sequence and information on the sequence tags thus obtained.
[0112] Subtraction hybridization is frequently used for cloning a
gene with different expression levels in various tissues or cells,
and can also be used to clone a gene specifically expressed in
dopaminergic neuron precursor cells of the present invention, or
cells differentiated, induced, or proliferated therefrom. First,
from the aforementioned cells of the present invention, a DNA
sample of cells to be tested is prepared (hereinafter referred to
as test DNA). Next, DNA of cells to be compared is prepared
(hereinafter referred to as driver DNA). The test DNA and the
driver DNA can also be used interchangeably. In any case, genes
present in the test DNA but not present in the driver DNA are
detected. Next, the prepared test DNA is mixed with a large excess
of driver DNA, and denatured to form single-stranded DNA, followed
by annealing. A specific sequence not present in the driver DNA can
be isolated as double-stranded DNA comprising only the test DNA
sequence by regulating the annealing conditions. See, Swaroop et
al. (1991) Nucleic Acids Res. 19: 1954 and Yasunaga et al. (1999)
Nature Genet. 21: 363-9, for further details on this method.
[0113] The RDA method is a method that uses PCR to selectively
amplify a sequence of the test DNA that is not present in the
driver DNA, and can be similarly used in the present invention like
the other previously described methods. See, Lisitsyn (1995) Trends
Genet. 11: 303-7 and Schutte et al. (1995) Proc. Natl. Acad. Sci.
USA 92: 5950-4, for more details on the procedure.
[0114] Genes specific to dopaminergic neuron precursor cells, or
cells differentiated, induced, or proliferated therefrom, are
detected and isolated as described, and can be inserted into
vectors or such, for sequence determination and expression analysis
using the various known methods described above.
<Screening Using Precursor Cell Maturation as an Index>
[0115] The present invention provides a screening method that
comprises a step of contacting a test substance with dopaminergic
neuron precursor cells of the present invention, and a step of
detecting differentiation or proliferation of the precursor cells
resulting from that contact. Since compounds obtained by this
screening method demonstrate a regulatory function in the
differentiation, proliferation, and such, of dopaminergic neurons,
they are considered useful as potential therapeutic candidates for
diseases caused by defects in dopaminergic neurons.
[0116] Here, the "test substance" may be any type of compound,
examples of which include the expression products of gene
libraries, synthetic low molecular weight compound libraries,
synthetic peptide libraries, antibodies, substances released by
bacteria, cell (microbial, plant, or animal) extracts, cell
(microbial, plant, or animal) culture supernatants, purified or
partially purified polypeptides, marine organisms, plant or animal
extracts, soil, random phage peptide display libraries, and
such.
[0117] Cell differentiation and proliferation can be detected by
comparing with the status of the cell in the absence of the test
substance. Cell differentiation and proliferation may be detected
by morphological observation under a microscope or by detection and
quantification of substances produced in cells, such as
dopamine.
<Analysis of 65B13 Expression Regulatory Region>
[0118] The present invention provides an expression regulatory
region of 65B13. An expression regulatory region of the present
invention can be cloned from genomic DNA by known methods using a
polynucleotide of the present invention. For example, a method for
establishing the transcriptional start site, such as the SI mapping
method, is known and can be used in the present invention (Cell
Engineering, Supplement 8, New Cell Engineering Experiment
Protocol, Cancer Research Division, The Institute of Medical
Science, The University of Tokyo ed., Shujunsha Publishing (1993)
pp. 362-374). In general, the expression regulatory region of a
gene can be cloned by screening a genomic DNA library, using a
probe DNA comprising a 15-100 bp segment, and preferably a 30-50 bp
segment, of the gene's 5' terminus (in the present invention, all
or a portion of nucleotides 1 to 176 of SEQ ID NO: 1, or
nucleotides 1 to 126 of SEQ ID NO: 2). A clone obtained in this
manner contains a 5' non-coding region of 10 kbp or more, and is
shortened or fragmented by exonuclease treatment, or such. Finally,
the shortened sequence portion comprising a potential expression
regulatory region is evaluated for its expression, strength,
regulation, and such, using a reporter gene, thereby making it
possible to determine the minimum unit required for maintaining the
activity of the 65B13 expression regulatory region of the present
invention.
[0119] Gene expression regulatory regions can be predicted using a
program such as Neural Network
(http://www.fruitfly.org./seq_tools/promoter.html; Reese et al.,
Biocomputing: Proceedings of the 1996 Pacific Symposium, Hunter and
Klein ed., World Scientific Publishing Co., Singapore, (1996)).
Moreover, a program for predicting the minimum unit required for
the activity of an expression regulatory region is also known,
(http://biosci.cbs.umn.edu./software/proscan/promoterscan.htm;
Prestridge (1995) J. Mol. Biol. 249: 923-932), and can be used in
the present invention.
[0120] The expression regulatory region of the 65B13 gene isolated
in this manner can be used to produce a protein of interest
specific for postmitotic dopaminergic neuron precursor cells in
vivo.
<Ligand Identification>
[0121] The present invention provides ligands against the
polypeptides of the present invention. The polypeptides of the
present invention have a transmembrane domain, and thus are thought
to exist embedded within the cell membrane in nature. These
polypeptides are believed to be involved in neuron maturation
because of their transient expression in dopaminergic neuron
precursor cells immediately after cell cycle exit. Thus, potential
ligands that may demonstrate an agonistic or antagonistic function
towards a polypeptide of the present invention may be used for
regulating the differentiation of dopaminergic neurons in vivo, ex
vivo, and in vitro. In identifying a ligand for a polypeptide of
the present invention, a polypeptide of the present invention and a
candidate compound are first contacted and tested for the presence
of binding. In this case, a polypeptide of the present invention
can be used when immobilized on a support, or embedded in the cell
membrane. There are no particular limitations on the candidate
compounds, examples of which include expression products of gene
libraries, natural substances derived from marine organisms,
extracts of various types of cells, known compounds and peptides,
natural substances derived from plants, body tissue extracts,
microbial culture supernatants and peptide groups randomly produced
by the phage display method (J. Mol. Biol. 222: 301-10 (1991)). In
addition, the candidate compound may be labeled for detection of
binding.
BEST MODE FOR CARRYING OUT THE INVENTION
[0122] The present invention will be explained in more detail with
reference to examples, but it is not to be construed as being
limited thereto.
EXAMPLE 1
Isolation and Sequence Analysis of a Gene Specific for Dopaminergic
Neuron Precursor Cells
[0123] To isolate a gene specific to dopaminergic neuron precursor
cells, genes with differences in expression were amplified by the
subtraction (N-RDA) method using RNA from ventral and dorsal
midbrain of E12.5 mice, and sequences of the resulting genes were
analyzed.
1. N-RDA Method
1-1. Adapter Preparation
[0124] The following oligonucleotides were annealed to each other,
and prepared at 100 .mu.M. (ad2: ad2S+ad2A, ad3: ad3S+ad3A, ad4:
ad4S+ad4A, ad5: ad5S+ad5A, ad13: ad13S+ad13A) TABLE-US-00001 ad2S:
cagctccacaacctacatcattccgt (SEQ ID NO:11) ad2A: acggaatgatgt (SEQ
ID NO:12) ad3S: gtccatcttctctctgagactctggt (SEQ ID NO:13) ad3A:
accagagtctca (SEQ ID NO:14) ad4S: ctgatgggtgtcttctgtgagtgtgt (SEQ
ID NO:15) ad4A: acacacteacag (SEQ ID NO:16) ad5S:
ccagcatcgagaatcagtgtgacagt (SEQ ID NO:17) ad5A: actgtcacactg (SEQ
ID NO:18) ad13S: gtcgatgaacttcgactgtcgatcgt (SEQ ID NO:19) ad13A:
acgatcgacagt. (SEQ ID NO:20)
1-2. cDNA Synthesis
[0125] Total RNA was prepared from the ventral and dorsal midbrain
regions of E12.5 mouse embryos (Japan SLC) using the RNeasy Mini
Kit (Qiagen), and double-stranded cDNA is synthesized using a cDNA
Synthesis Kit (Takara). After digestion with restriction enzyme
RsaI, ad2 was added. The cDNA was amplified by a 5-minute
incubation at 72.degree. C., 15 PCR cycles of 30 seconds at
94.degree. C., 30 seconds at 65.degree. C., and 2 minutes at
72.degree. C., and a final 2-minute incubation at 72.degree. C.
using ad2S as the primer. In all cases, N-RDA PCR was carried out
using a reaction solution containing the following components.
[0126] 10.times. ExTaq 5 .mu.l
[0127] 2.5 mM dNTP 4 .mu.l
[0128] ExTaq 0.25 .mu.l
[0129] 100 .mu.M primer 0.5 .mu.l
[0130] cDNA 2 .mu.l
[0131] Distilled water 38.25 .mu.l
1-3. Driver Production
[0132] The ad2S amplified cDNA was further amplified by incubating
at 94.degree. C. for 2 minutes, and then performing five PCR cycles
of 30 seconds at 94.degree. C., 30 seconds at 65.degree. C., and 2
minutes at 72.degree. C., and a final 2-minute incubation at
72.degree. C. The cDNA was purified using the Qiaquick PCR
Purification Kit (Qiagen), and digested with RsaI. 3 .mu.g was used
for each round of subtraction.
1-4. Tester Production
[0133] The ad2S amplified cDNA was further amplified by incubating
at 94.degree. C. for 2 minutes, and then performing five PCR cycles
of 30 seconds at 94.degree. C., 30 seconds at 65.degree. C., and 2
minutes at 72.degree. C., and a final 2-minute incubation at
72.degree. C. The cDNA was purified using the Qiaquick PCR
Purification Kit (Qiagen), and digested with RsaI. ad3 was added to
60 ng of the RsaI-digested cDNA.
1-5. First Round of Subtraction
[0134] The tester and the driver produced in Sections 1-3 and 1-4
above were mixed, ethanol precipitated, and then dissolved in 1
.mu.l of 1.times.PCR buffer. After a 5-minute incubation at
98.degree. C., 1 .mu.l of 1.times.PCR buffer+1M NaCl was added.
After another 5 minutes of incubation at 98.degree. C., the tester
and the driver were hybridized at 68.degree. C. for 16 hours.
[0135] With ad3S as the primer, the hybridized cDNA was amplified
by incubating at 72.degree. C. for 5 minutes, and performing 10
cycles of 30 seconds at 94.degree. C., 30 seconds at 65.degree. C.,
and 2 minutes at 72.degree. C. Next, the amplified cDNA was
digested with the Mung Bean Nuclease (Takara) and purified using
the Qiaquick PCR Purification Kit. Then, it was amplified by
incubating at 94.degree. C. for 2 minutes, and performing 13 PCR
cycles of 30 seconds at 94.degree. C., 30 seconds at 65.degree. C.,
and 2 minutes at 72.degree. C., and a final 2-minute incubation at
72.degree. C.
1-6. Normalization
[0136] 1 .mu.l of 2.times.PCR buffer was added to 8 ng of the cDNA
amplified in the first round of subtraction. After incubating at
98.degree. C. for 5 minutes, 2 .mu.l of 1.times.PCR buffer+1 M NaCl
was added. After another 5 minutes of incubation at 98.degree. C.,
the cDNA was hybridized at 68.degree. C. for 16 hours.
[0137] The hybridized cDNA was digested with RsaI, and purified
using the Qiaquick PCR Purification Kit. Then, it was amplified
with ad3S as the primer by incubating at 94.degree. C. for 2
minutes, and performing 11 PCR cycles of 30 seconds at 94.degree.
C., 30 seconds at 65.degree. C., and 2 minutes at 72.degree. C.,
and a final 2-minute incubation at 72.degree. C. The PCR product
was then digested with RsaI, followed by the addition of ad4.
1-7.5 Second Round of Subtraction
[0138] 20 ng of cDNA to which ad4 was added in Section 1-6 above
was used as the tester and mixed with the driver of 1-3 above, and
the same subtraction procedure used in Section 1-5 above was
performed. Finally, ad5 was added to the cDNA following RsaI
digestion.
1-8. Third Round of Subtraction
[0139] 2 ng of cDNA to which ad5 was added in section 1-7 above was
used as the tester and mixed with the driver of 1-3 above, and the
same subtraction procedure used in section 1-5 above was carried
out. Finally, ad13 was added to the RsaI-digested cDNA.
1-9. Fourth Round of Subtraction
[0140] 2 ng of cDNA to which ad13 was added in section 1-8 above
was used as the tester and mixed with the driver of 1-3 above, and
the same subtraction procedure used in Section 1-5 above was
carried out. The amplified cDNA was cloned into pCRII vector
(Invitrogen), and its nucleotide sequence was analyzed using the
ABI3100 sequence analyzer.
[0141] Next, RACE was carried out according to the method described
below, using the 65B13 fragment sequence obtained by the N-RDA
method.
[0142] 2. RACE Method
[0143] Total RNA was prepared from the brain of a E12.5 mouse
embryo by RNeasy Mini Kit (Qiagen) to prepare mRNA using the .mu.M
ACS mRNA Isolation Kit (Miltenyi Biotec). A cDNA library was then
prepared from the prepared mRNA using the Superscript Choice System
(Invitrogen) and pCRII vector (Invitrogen). Plasmid DNA was then
prepared from this cDNA library. PCR was carried out using the
following primers: TABLE-US-00002 TAU2: GGCTTTACACTTTATGCTTCCGGCTC
(SEQ ID NO:21) TAU4: CAGCTATGACCATGATTACGCCAAGC (SEQ ID NO:22)
TAD3: AGGCGATTAAGTTGGGTAACGCCAGG (SEQ ID NO:23) TAD4:
CCAGTCACGACGTTGTAAAACGACGG (SEQ ID NO:24) 65B13 F1:
CTTCCCGTATGCTACCTTGTCTCCAC (SEQ ID NO:25) 65B13 F2:
TCCATCTCTCCAAGTGAAGGGTCTTG (SEQ ID NO:26) 65B13 R1:
CCAACAGTCCTGCATGCTTGTAATGA (SEQ ID NO:27) 65B13 R2:
TCCTTCAATGTTCAGTTTTGGAGGGG (SEQ ID NO:28)
[0144] The PCR conditions are indicated below.
[0145] 1st Round PCR:
[0146] 10.times. ExTaq 2 .mu.l
[0147] 2.5 mM dNTP 1.6 .mu.l
[0148] ExTaq 0.1 .mu.l
[0149] 100 .mu.M TAU2 or TAD3 0.04 .mu.l
[0150] 100 .mu.M 65B13 F1 or R1 0.2 .mu.l
[0151] cDNA (10 ng/.mu.l) 1 .mu.l
[0152] Distilled water 15.06 .mu.l
[0153] After incubating at 94.degree. C. for 5 minutes, 25 cycles
of 30 seconds at 94.degree. C., 30 seconds at 65.degree. C., and 5
minutes at 72.degree. C., and a final 2-minute incubation at
72.degree. C. were carried out. Next, the second round of PCR was
carried out using the 100-fold-diluted product obtained from first
round PCR. Conditions for the second round PCR are as shown
below.
[0154] 2nd Round of PCR:
[0155] 10.times. ExTaq 5 .mu.l
[0156] 2.5 mM dNTP 4 .mu.l
[0157] ExTaq 0.25 .mu.l
[0158] 100 .mu.M TAU4 or TAD4 0.1 .mu.l
[0159] 100 .mu.M 65B13 F2 or R20.5 .mu.l
[0160] 1/100 st PCR product 1 .mu.l
[0161] Distilled water 15.06 .mu.l
[0162] After incubating for 5 minutes at 94.degree. C., 25 cycles
of 30 seconds at 94.degree. C., 30 seconds at 65.degree. C., and 5
minutes at 72.degree. C., and a final 2-minute incubation at
72.degree. C. were carried out. The amplified cDNA fragment was
cloned into the pCRII vector and its sequence was analyzed using
the ABI3100 sequence analyzer.
[0163] The nucleotide sequences of the resulting two genes of
65B13-a and 65B13-b are shown as SEQ ID NO: 1 (FIGS. 1 and 2) and
SEQ ID NO: 2 (FIGS. 3 and 4). The coding region of 65B13-a begins
at the 177th "A" of SEQ ID NO: 1 and ends with the stop codon at
nucleotides 2278 to 2280, yielding a protein comprising 700 amino
acids. The 17 amino acid residues encoded by the sequence of
nucleotides 177 to 228 is the signal sequence. The 17 amino acid
residues encoded by the sequence of nucleotides 1717 to 1767 is the
transmembrane domain. In contrast, the coding region of 65B13-b
begins at the 127th "A" of SEQ ID NO: 2 and ends at the stop codon
of nucleotides 2077 to 2079, yielding a protein comprising 650
amino acids. The 17 amino acid residues encoded by the sequence of
nucleotides 127 to 177 is the signal sequence, and the 17 amino
acid residues encoded by the sequence of nucleotides 1516 to 1566
is the transmembrane domain. The amino acid sequences encoded by
the 65B13-a and 65B13-b genes are shown in SEQ ID NOs: 3 and 4. As
shown in FIG. 5, a comparison of the amino acid sequences encoded
by both genes revealed that 65B13-a and 65B13-b are isoforms that
have resulted from alternative splicing, and that 65B13-b lacks 50
amino acids at the N-terminus compared to 65B13-a. Based on the
homology search results, the proteins encoded by the 65B13 genes
are believed to be single transmembrane proteins with five Ig
domains as shown in FIG. 6.
EXAMPLE 2
Expression Analysis of the 65B13 Genes
[0164] Next, an expression analysis of these genes by in situ
hybridization was carried out according to the following
protocol.
[0165] First, E12.5 mouse embryos were embedded in O.C.T., and
fresh frozen sections of 16 .mu.m thickness were prepared. After
drying on a slide glass, the sections were fixed in 4% PFA at room
temperature for 30 minutes. After washing with PBS, hybridization
was carried out at 65.degree. C. for 40 hours (1 .mu.g/ml
DIG-labeled RNA probe, 50% formamide, 5.times.SSC, 1% SDS, 50
.mu.g/ml yeast RNA, 50 .mu.g/ml Heparin). Subsequently, the
sections were washed at 65.degree. C. (50% formamide, 5.times.SSC,
1% SDS) and then treated with RNase (5 .mu.g/ml RNase) at room
temperature for 5 minutes. After washing with 0.2.times.SSC at
65.degree. C. and washing with 1.times.TBST at room temperature,
blocking was carried out (Blocking reagent: Roche). The sections
were then reacted with alkaline phosphatase-labeled anti-DIG
antibody (DAKO), washed (1.times.TBST, 2 mM Levamisole), and color
developed using NBT/BCIP (DAKO) as the substrate.
[0166] The expression analysis results of these genes by in situ
hybridization showed that 65B13 is expressed in the ventral
midbrain region, cerebellar primordium, hindbrain, and spinal cord,
at the stage E12.5 which corresponds to the time of dopaminergic
neuron development (FIG. 7). 65B13 expression in the spinal cord
was further compared with those of the growth marker Ki67 and the
maturation marker NCAM. In the ventricular zone (VZ) where
Ki67-positive neural progenitors proliferate, 65B13 was expressed
in some cells. In contrast, 65B13 expression was not observed in
the mantle layer (ML), where matured NCAM-positive precursors that
have exited from the cell cycle exit (FIG. 8). Similarly in zones
outside the spinal cord, expression was observed in some cells
within VZ. According to these expression patterns, 65B13 was
thought to be expressed transiently in neural precursor cells
immediately after cell cycle exit.
[0167] In the midbrain, expression was only observed in the most
ventral region of the ventricular zone. Since tyrosine hydroxylase
(TH), a marker gene for dopaminergic neurons, is only expressed in
the ML, a comparison of the TH expression and the 65B13 expression
showed that both were not expressed in the same cells, however,
their expression regions along the dorsal-ventral axis were
completely overlapped (FIG. 9). In general, nerve cells present in
neural tubes are known to proliferate in the VZ, stop cell division
with the commencement of differentiation, and then mature after
migrating to the ML, which is just outside of the VZ. Thus,
progenitors of dopaminergic neurons are believed to proliferate in
the VZ adjacent to the TH expression zone, and express TH after
having migrated to the outside following the cell cycle exit. Since
this VZ region where these progenitors proliferate overlaps with
the 65B13 expression region, 65B13 is thought to express
specifically and transiently in dopaminergic neuron precursor cells
in the midbrain immediately after cell cycle exit (FIGS. 10 and
11).
EXAMPLE 3
Expression Analysis of the 65B13 Proteins
[0168] Next, a portion of the 65B13 gene sequence that encodes the
extracellular region was used to generate an anti-65B13 antibody to
be used for expression analysis by immunohistochemical
staining.
[0169] First, a partial sequence of the 65B13 gene that encodes the
extracellular region was introduced into 293E cells, and the
extracellular region of the 65B13 protein was expressed and
recovered. After immunizing hamsters with the recovered protein,
lymphocytes were extracted and fused with myeloma cells. The fused
cells were then transplanted into the abdominal cavities of mice,
ascites was obtained, and an anti-65B13 monoclonal antibody was
purified. Next, E12.5 mouse embryos were fixed in 4% PFA/PBS(-) at
4.degree. C. for 2 hours, and then stood overnight at 4.degree. C.
in 20% sucrose/PBS(-), followed by O.C.T. embedding. Sections of 12
um thickness were produced. After affixing to slide glasses, the
sections were dried for 30 minutes at room temperature and then
re-moistened with PBS(-). Subsequently, blocking (Block Ace) was
carried out at room temperature for 20 minutes. The tissue section
glasses were incubated with the generated anti-65B13 monoclonal
antibody (10 ug/ml, 2.5% Block Ace/PBS), anti-TH antibody
(Chemicon, 0.7 ug/ml, 2.5% Block Ace/PBS), and anti-Nurr1 antibody
(Santa Cruz, 4 ug/ml, 2.5% Block Ace/PBS) for 1 hour at room
temperature, and overnight at 4.degree. C. The tissue section
glasses were then washed four times with 0.1% Triton X-100/PBS(-)
at room temperature for 10 minutes each, and incubated with
Cy3-labeled anti-hamster IgG antibody, FITC-labeled anti-rabbit IgG
antibody, and Cy5-labeled anti-mouse IgG antibody (Jackson, 10
ug/ml, 2.5% Block Ace) at room temperature for 1 hour. The glasses
were washed in the same manner, followed by an additional 10-minute
wash with PBS(-) at room temperature, and were then embedded.
[0170] Similarly to the expression analysis by in situ
hybridization, expression analysis by immunohistochemical staining
using the produced anti-65B13 monoclonal antibody showed that 65B13
was expressed in the ventral midbrain region at E12.5, which
corresponds to the time of dopaminergic neuron development (FIG.
13). A comparison of the 65B13 protein expression with those of the
dopaminergic neuron markers TH and Nurr1 protein, revealed that
65B13 protein was expressed in the VZ side of the ventral-most
region of the midbrain where TH and Nurr1 protein are expressed.
Thus, 65B13 protein was thought to express in dopaminergic neuron
precursor cells.
EXAMPLE 4
Detection of 65B13-Expressing Cells by Flow Cytometry
[0171] Next, cells that express 65B13 were detected by flow
cytometry using an anti-65B13 monoclonal antibody.
[0172] First, the ventral midbrain region excised from E12.5 mouse
embryos, or cell populations comprising dopaminergic neuron
precursor cells that have differentiated from ES cells in vitro,
were dispersed in a cell dissociation buffer (Invitrogen). Then,
the samples were stained for 20 minutes at 4.degree. C. with an
anti-65B13 monoclonal antibody (10 ug/ml, 1% fetal calf serum, 1 mM
EDTA/PBS), without prior fixation or permeation. Subsequently, the
samples were washed three times with 1% fetal calf serum and 1 mM
EDTA/PBS(-) at 4.degree. C. for 3 minutes, stained with PE-labeled
anti-hamster IgG antibody (Pharmingen, 4 ug/ml, 1% fetal calf
serum, 1 mM EDTA/PBS) at 4.degree. C. for 20 minutes, and then
washed in the same manner. The 65B13-expressing cells were then
detected by flow cytometry.
[0173] Populations of cells expressing the 65B13 proteins were
detected by flow cytometry using the generated anti-65B13
monoclonal antibody (FIG. 14). Since 65B13-expressing cells can be
detected without fixation or permeation, 65B13-expressing cells are
believed to be separable as viable cells, by using a flow cytometer
equipped with a cell sorter. Since 65B13 protein is thought to
express in dopaminergic neuron precursor cells, 65B13 is believed
to be useful for the separation of dopaminergic neuron precursor
cells.
INDUSTRIAL APPLICABILITY
[0174] A novel 65B13 gene expressed specifically and transiently in
dopaminergic neuron precursor cells immediately after cell cycle
exit was obtained according to the present invention. The cellular
expression of 65B13 can be used as an indicator in selecting
suitable cells to be used in transplant therapy for
neurodegenerative diseases such as Parkinson's disease, in terms of
their safety, survival rate, and network formation ability. In
addition, since dopaminergic neuron precursor cells immediately
after cell cycle exit are selectively obtained, they can be easily
differentiated into an appropriate state in vitro when used in
therapy that require mature cells. Moreover, dopaminergic neuron
precursor cells obtained using the genes of the present invention
can also be used to isolate genes specifically expressed in these
cells. The cells are also thought to be useful in developing
pharmaceuticals for neurodegenerative diseases such as Parkinson's
disease. Since dopaminergic neuron precursor cells immediately
after cell cycle exit are precursor cells involved in early neuron
formation, they are useful in elucidating the neuron maturation
process, namely, identifying various factors involved in the
maturation process. Elucidation of these factors is expected to
contribute greatly to the treatment of neurodegenerative diseases.
Moreover, maturation of these cells can be used as an index for
screening substances that may regulate (inhibit or promote) the
maturation process.
Sequence CWU 1
1
28 1 2876 DNA Mus musculus 1 gatgagccag atttcgggga ctctgggcca
gacataaaat cttccagccc ggagagaatt 60 gtgtgcagag aggggctcca
gtccagcgtg gtgtgagagg cgtgctatca agaaagaagt 120 tggaggggaa
ccagtgcaac cctaactcta cgagatcttg gggtacacac actcgggatg 180
ctggcctccg ccctcctcgt tttcctttgc tgtttcaaag gacatgcagg ctcatcgccc
240 catttcctac aacagccaga ggacatggtg gtgctgttgg gggaggaagc
ccggctgccc 300 tgcgctctgg gcgcgtacag ggggctcgtg cagtggacta
aggatgggct ggctctaggg 360 ggcgaaagag accttccagg gtggtcccgg
tactggatat cggggaattc agccagtggc 420 cagcatgacc tccacattaa
gcctgtggaa ttggaagatg aggcatcgta tgagtgccag 480 gcttcgcaag
caggtctccg atcacgacca gcccaactgc acgtgatggt ccccccagaa 540
gctccccagg tactaggcgg cccctctgtg tctctggttg ctggagttcc tggaaatctg
600 acctgtcgga gtcgtgggga ttcccgacct gcccctgaac tactgtggtt
ccgagatggg 660 atccggctgg atgcgagcag cttccaccag accacgctga
aggacaaggc cactggaaca 720 gtggaaaaca ccttattcct gaccccttcc
agtcatgatg atggcgccac cttgatctgc 780 agagcgcgaa gccaggccct
gcccacaggg agggacacag ctgttacact gagccttcag 840 tatcccccaa
tggtgactct gtctgctgag ccccagactg tgcaggaggg agagaaggtg 900
actttcctgt gtcaagccac tgcccagcct cctgtcactg gctacaggtg ggcgaagggg
960 ggatccccgg tgctcggggc acgtgggcca aggttggagg tcgttgcaga
tgccactttc 1020 ctgactgagc cggtgtcctg cgaggtcagc aacgcggtcg
gaagcgccaa ccgcagcacg 1080 gcgctggaag tgttgtatgg acccattctg
caggcaaaac ctaagtccgt gtccgtggac 1140 gtggggaaag atgcctcctt
cagctgtgtc tggcgcggga acccacttcc acggataacc 1200 tggacccgca
tgggtggctc tcaggtgctg agctccgggc ccacgctgcg gcttccgtcc 1260
gtggcactgg aggatgcggg cgactatgta tgcagggctg agccgaggag aacgggtctg
1320 ggaggcggca aagcgcaggc gaggctgact gtgaacgcac cccctgtagt
gacagccctg 1380 caacctgcac cagcctttct gaggggtcct gctcgcctcc
agtgtgtggt gtttgcctcc 1440 cctgccccag actcggtggt ttggtcttgg
gacgagggct tcttggaggc aggctcactg 1500 ggcaggttcc tagtggaagc
cttcccagcc ccggaagtgg aggggggaca gggccctggc 1560 cttatttctg
tgctacacat ttccggaacc caggagtccg actttaccac cggcttcaac 1620
tgcagtgccc gcaaccggct aggagaggga cgagtccaga tccacttggg ccgtagagat
1680 ttgctgccta ctgtccggat tgtggctggt gcagcatctg cagccacctc
tctccttatg 1740 gtcatcactg gagtggtcct ctgctgctgg cgccatggct
ctctctctaa gcaaaagaac 1800 ttggtccgga tcccaggaag cagcgagggt
tccagttcac gtggccctga ggaggagaca 1860 ggcagcagtg aggaccgggg
tcccattgtg cacaccgacc acagtgattt ggttcttgag 1920 gaaaaagagg
ctctggagac aaaggatcca accaacggtt actacaaggt tcgaggggtc 1980
agtgtgagcc ttagccttgg ggaagctcct ggaggaggcc tcttcttgcc accgccctct
2040 ccgatcggtc tcccagggac tcctacttac tatgacttca agccacatct
ggacttagtc 2100 cctccctgca gactgtacag agcgagggca ggttatctta
ccacccccca tccccgtgcc 2160 ttcaccagct acatgaaacc cacatccttt
ggacccccag atttgagctc tggaactccc 2220 cccttcccgt atgctacctt
gtctccaccc agccaccagc gtctccagac tcatgtgtga 2280 atccatctct
ccaagtgaag ggtcttggaa tcttctgttt gccatatagt gtgttgtcca 2340
gatttctggg gagtcagaac aagttgatga ccaacccctc caaaactgaa cattgaagga
2400 gggaaagatc attacaagca tcaggactgt tggtgtacac tcagttcagc
caaagtggat 2460 tctccaagtg ggagcaatat ggccgctttc ccatgagaaa
gacattcaag atggtgacta 2520 aatgactaaa tactttgcag agggacaaag
atgggaacta gggatacgga tggaagtagt 2580 agagaagata tatgaccatc
tgcatcaaga ggaaggataa catatgacaa atcaagatga 2640 aagaaataat
ccaccccacc cccaccgcgt cctggccaat aagtatagcc tacatggctg 2700
ttcattatct gggaaccaaa atggccacta tcttgactcc ttccttaaag atacagaaag
2760 aattgaatcc aaggaatggg gtagggtgga aatagaagaa atgaagggga
ctcttgggct 2820 aagaatactt atgtttaata ataaaagggg gaggcaaaga
tgcaaaaaaa aaaaaa 2876 2 2243 DNA Mus musculus 2 gagagaattg
tgtgcagaga gaggctccag tccagcgtgg tgtgagaggc gtgctatcaa 60
gaaagaagtt ggaggggaac cagtgcaacc ctaactctac gagatcttgg ggtacacaca
120 ctcgggatgc tggcctccgc cctcctcgtt ttcctttgct gtttcaaagg
acatgcaggg 180 tggtcccggt actggatatc ggggaattca gccagtggcc
agcatgacct ccacattaag 240 cctgtggaat tggaagatga ggcatcgtat
gagtgccagg cttcgcaagc aggtctccga 300 tcacgaccag cccaactgca
cgtgatggtc cccccagaag ctccccaggt actaggcggc 360 ccctctgtgt
ctctggttgc tggagttcct ggaaatctga cctgtcggag tcgtggggat 420
tcccgacctg cccctgaact actgtggttc cgagatggga tccggctgga tgcgagcagc
480 ttccaccaga ccacgctgaa ggacaaggcc actggaacag tggaaaacac
cttattcctg 540 accccttcca gtcatgatga tggcgccacc ttgatctgca
gagcgcgaag ccaggccctg 600 cccacaggga gggacacagc tgttacactg
agccttcagt atcccccaat ggtgactctg 660 tctgctgagc cccagactgt
gcaggaggga gagaaggtga ctttcctgtg tcaagccact 720 gcccagcctc
ctgtcactgg ctacaggtgg gcgaaggggg gatccccggt gctcggggca 780
cgtgggccaa ggttggaggt cgttgcagat gccactttcc tgactgagcc ggtgtcctgc
840 gaggtcagca acgcggtcgg aagcgccaac cgcagcacgg cgctggaagt
gttgtatgga 900 cccattctgc aggcaaaacc taagtccgtg tccgtggacg
tggggaaaga tgcctccttc 960 agctgtgtct ggcgcgggaa cccacttcca
cggataacct ggacccgcat gggtggctct 1020 caggtgctga gctccgggcc
cacgctgcgg cttccgtccg tggcactgga ggatgcgggc 1080 gactatgtat
gcagggctga gccgaggaga acgggtctgg gaggcggcaa agcgcaggcg 1140
aggctgactg tgaacgcacc ccctgtagtg acagccctgc aacctgcacc agcctttctg
1200 aggggtcctg ctcgcctcca gtgtgtggtg tttgcctccc ctgccccaga
ctcggtggtt 1260 tggtcttggg acgagggctt cttggaggca ggctcactgg
gcaggttcct agtggaagcc 1320 ttcccagccc cggaagtgga ggggggacag
ggccctggcc ttatttctgt gctacacatt 1380 tccggaaccc aggagtccga
ctttaccacc ggcttcaact gcagtgcccg caaccggcta 1440 ggagagggac
gagtccagat ccacttgggc cgtagagatt tgctgcctac tgtccggatt 1500
gtggctggtg cagcatctgc agccacctct ctccttatgg tcatcactgg agtggtcctc
1560 tgctgctggc gccatggctc tctctctaag caaaagaact tggtccggat
cccaggaagc 1620 agcgagggtt ccagttcacg tggccctgag gaggagacag
gcagcagtga ggaccggggt 1680 cccattgtgc acaccgacca cagtgatttg
gttcttgagg aaaaagaggc tctggagaca 1740 aaggatccaa ccaacggtta
ctacaaggtt cgaggggtca gtgtgagcct tagccttggg 1800 gaagctcctg
gaggaggcct cttcttgcca ccgccctctc cgatcggtct cccagggact 1860
cctacttact atgacttcaa gccacatcag gacttagtcc ctccctgcag actgtacaga
1920 gcgagggcag gttatcttac caccccccat ccccgtgcct tcaccagcta
catgaaaccc 1980 acatcctttg gacccccaga tttgagctct ggaactcccc
ccttcccgta tgctaccttg 2040 tctccaccca gccaccagcg tctccagact
catgtgtgaa tccatctctc caagtgaagg 2100 gtcttggaat cttctgtttg
ccatatagtg tgttgtccag atttctgggg agtcagaaca 2160 agttgatgac
caacccctcc aaaactgaac attgaaggag ggaaagatca ttacaagcat 2220
caggactgtt ggtgtacact cag 2243 3 700 PRT Mus musculus 3 Met Leu Ala
Ser Ala Leu Leu Val Phe Leu Cys Cys Phe Lys Gly His 1 5 10 15 Ala
Gly Ser Ser Pro His Phe Leu Gln Gln Pro Glu Asp Met Val Val 20 25
30 Leu Leu Gly Glu Glu Ala Arg Leu Pro Cys Ala Leu Gly Ala Tyr Arg
35 40 45 Gly Leu Val Gln Trp Thr Lys Asp Gly Leu Ala Leu Gly Gly
Glu Arg 50 55 60 Asp Leu Pro Gly Trp Ser Arg Tyr Trp Ile Ser Gly
Asn Ser Ala Ser 65 70 75 80 Gly Gln His Asp Leu His Ile Lys Pro Val
Glu Leu Glu Asp Glu Ala 85 90 95 Ser Tyr Glu Cys Gln Ala Ser Gln
Ala Gly Leu Arg Ser Arg Pro Ala 100 105 110 Gln Leu His Val Met Val
Pro Pro Glu Ala Pro Gln Val Leu Gly Gly 115 120 125 Pro Ser Val Ser
Leu Val Ala Gly Val Pro Gly Asn Leu Thr Cys Arg 130 135 140 Ser Arg
Gly Asp Ser Arg Pro Ala Pro Glu Leu Leu Trp Phe Arg Asp 145 150 155
160 Gly Ile Arg Leu Asp Ala Ser Ser Phe His Gln Thr Thr Leu Lys Asp
165 170 175 Lys Ala Thr Gly Thr Val Glu Asn Thr Leu Phe Leu Thr Pro
Ser Ser 180 185 190 His Asp Asp Gly Ala Thr Leu Ile Cys Arg Ala Arg
Ser Gln Ala Leu 195 200 205 Pro Thr Gly Arg Asp Thr Ala Val Thr Leu
Ser Leu Gln Tyr Pro Pro 210 215 220 Met Val Thr Leu Ser Ala Glu Pro
Gln Thr Val Gln Glu Gly Glu Lys 225 230 235 240 Val Thr Phe Leu Cys
Gln Ala Thr Ala Gln Pro Pro Val Thr Gly Tyr 245 250 255 Arg Trp Ala
Lys Gly Gly Ser Pro Val Leu Gly Ala Arg Gly Pro Arg 260 265 270 Leu
Glu Val Val Ala Asp Ala Thr Phe Leu Thr Glu Pro Val Ser Cys 275 280
285 Glu Val Ser Asn Ala Val Gly Ser Ala Asn Arg Ser Thr Ala Leu Glu
290 295 300 Val Leu Tyr Gly Pro Ile Leu Gln Ala Lys Pro Lys Ser Val
Ser Val 305 310 315 320 Asp Val Gly Lys Asp Ala Ser Phe Ser Cys Val
Trp Arg Gly Asn Pro 325 330 335 Leu Pro Arg Ile Thr Trp Thr Arg Met
Gly Gly Ser Gln Val Leu Ser 340 345 350 Ser Gly Pro Thr Leu Arg Leu
Pro Ser Val Ala Leu Glu Asp Ala Gly 355 360 365 Asp Tyr Val Cys Arg
Ala Glu Pro Arg Arg Thr Gly Leu Gly Gly Gly 370 375 380 Lys Ala Gln
Ala Arg Leu Thr Val Asn Ala Pro Pro Val Val Thr Ala 385 390 395 400
Leu Gln Pro Ala Pro Ala Phe Leu Arg Gly Pro Ala Arg Leu Gln Cys 405
410 415 Val Val Phe Ala Ser Pro Ala Pro Asp Ser Val Val Trp Ser Trp
Asp 420 425 430 Glu Gly Phe Leu Glu Ala Gly Ser Leu Gly Arg Phe Leu
Val Glu Ala 435 440 445 Phe Pro Ala Pro Glu Val Glu Gly Gly Gln Gly
Pro Gly Leu Ile Ser 450 455 460 Val Leu His Ile Ser Gly Thr Gln Glu
Ser Asp Phe Thr Thr Gly Phe 465 470 475 480 Asn Cys Ser Ala Arg Asn
Arg Leu Gly Glu Gly Arg Val Gln Ile His 485 490 495 Leu Gly Arg Arg
Asp Leu Leu Pro Thr Val Arg Ile Val Ala Gly Ala 500 505 510 Ala Ser
Ala Ala Thr Ser Leu Leu Met Val Ile Thr Gly Val Val Leu 515 520 525
Cys Cys Trp Arg His Gly Ser Leu Ser Lys Gln Lys Asn Leu Val Arg 530
535 540 Ile Pro Gly Ser Ser Glu Gly Ser Ser Ser Arg Gly Pro Glu Glu
Glu 545 550 555 560 Thr Gly Ser Ser Glu Asp Arg Gly Pro Ile Val His
Thr Asp His Ser 565 570 575 Asp Leu Val Leu Glu Glu Lys Glu Ala Leu
Glu Thr Lys Asp Pro Thr 580 585 590 Asn Gly Tyr Tyr Lys Val Arg Gly
Val Ser Val Ser Leu Ser Leu Gly 595 600 605 Glu Ala Pro Gly Gly Gly
Leu Phe Leu Pro Pro Pro Ser Pro Ile Gly 610 615 620 Leu Pro Gly Thr
Pro Thr Tyr Tyr Asp Phe Lys Pro His Leu Asp Leu 625 630 635 640 Val
Pro Pro Cys Arg Leu Tyr Arg Ala Arg Ala Gly Tyr Leu Thr Thr 645 650
655 Pro His Pro Arg Ala Phe Thr Ser Tyr Met Lys Pro Thr Ser Phe Gly
660 665 670 Pro Pro Asp Leu Ser Ser Gly Thr Pro Pro Phe Pro Tyr Ala
Thr Leu 675 680 685 Ser Pro Pro Ser His Gln Arg Leu Gln Thr His Val
690 695 700 4 650 PRT Mus musculus 4 Met Leu Ala Ser Ala Leu Leu
Val Phe Leu Cys Cys Phe Lys Gly His 1 5 10 15 Ala Gly Trp Ser Arg
Tyr Trp Ile Ser Gly Asn Ser Ala Ser Gly Gln 20 25 30 His Asp Leu
His Ile Lys Pro Val Glu Leu Glu Asp Glu Ala Ser Tyr 35 40 45 Glu
Cys Gln Ala Ser Gln Ala Gly Leu Arg Ser Arg Pro Ala Gln Leu 50 55
60 His Val Met Val Pro Pro Glu Ala Pro Gln Val Leu Gly Gly Pro Ser
65 70 75 80 Val Ser Leu Val Ala Gly Val Pro Gly Asn Leu Thr Cys Arg
Ser Arg 85 90 95 Gly Asp Ser Arg Pro Ala Pro Glu Leu Leu Trp Phe
Arg Asp Gly Ile 100 105 110 Arg Leu Asp Ala Ser Ser Phe His Gln Thr
Thr Leu Lys Asp Lys Ala 115 120 125 Thr Gly Thr Val Glu Asn Thr Leu
Phe Leu Thr Pro Ser Ser His Asp 130 135 140 Asp Gly Ala Thr Leu Ile
Cys Arg Ala Arg Ser Gln Ala Leu Pro Thr 145 150 155 160 Gly Arg Asp
Thr Ala Val Thr Leu Ser Leu Gln Tyr Pro Pro Met Val 165 170 175 Thr
Leu Ser Ala Glu Pro Gln Thr Val Gln Glu Gly Glu Lys Val Thr 180 185
190 Phe Leu Cys Gln Ala Thr Ala Gln Pro Pro Val Thr Gly Tyr Arg Trp
195 200 205 Ala Lys Gly Gly Ser Pro Val Leu Gly Ala Arg Gly Pro Arg
Leu Glu 210 215 220 Val Val Ala Asp Ala Thr Phe Leu Thr Glu Pro Val
Ser Cys Glu Val 225 230 235 240 Ser Asn Ala Val Gly Ser Ala Asn Arg
Ser Thr Ala Leu Glu Val Leu 245 250 255 Tyr Gly Pro Ile Leu Gln Ala
Lys Pro Lys Ser Val Ser Val Asp Val 260 265 270 Gly Lys Asp Ala Ser
Phe Ser Cys Val Trp Arg Gly Asn Pro Leu Pro 275 280 285 Arg Ile Thr
Trp Thr Arg Met Gly Gly Ser Gln Val Leu Ser Ser Gly 290 295 300 Pro
Thr Leu Arg Leu Pro Ser Val Ala Leu Glu Asp Ala Gly Asp Tyr 305 310
315 320 Val Cys Arg Ala Glu Pro Arg Arg Thr Gly Leu Gly Gly Gly Lys
Ala 325 330 335 Gln Ala Arg Leu Thr Val Asn Ala Pro Pro Val Val Thr
Ala Leu Gln 340 345 350 Pro Ala Pro Ala Phe Leu Arg Gly Pro Ala Arg
Leu Gln Cys Val Val 355 360 365 Phe Ala Ser Pro Ala Pro Asp Ser Val
Val Trp Ser Trp Asp Glu Gly 370 375 380 Phe Leu Glu Ala Gly Ser Leu
Gly Arg Phe Leu Val Glu Ala Phe Pro 385 390 395 400 Ala Pro Glu Val
Glu Gly Gly Gln Gly Pro Gly Leu Ile Ser Val Leu 405 410 415 His Ile
Ser Gly Thr Gln Glu Ser Asp Phe Thr Thr Gly Phe Asn Cys 420 425 430
Ser Ala Arg Asn Arg Leu Gly Glu Gly Arg Val Gln Ile His Leu Gly 435
440 445 Arg Arg Asp Leu Leu Pro Thr Val Arg Ile Val Ala Gly Ala Ala
Ser 450 455 460 Ala Ala Thr Ser Leu Leu Met Val Ile Thr Gly Val Val
Leu Cys Cys 465 470 475 480 Trp Arg His Gly Ser Leu Ser Lys Gln Lys
Asn Leu Val Arg Ile Pro 485 490 495 Gly Ser Ser Glu Gly Ser Ser Ser
Arg Gly Pro Glu Glu Glu Thr Gly 500 505 510 Ser Ser Glu Asp Arg Gly
Pro Ile Val His Thr Asp His Ser Asp Leu 515 520 525 Val Leu Glu Glu
Lys Glu Ala Leu Glu Thr Lys Asp Pro Thr Asn Gly 530 535 540 Tyr Tyr
Lys Val Arg Gly Val Ser Val Ser Leu Ser Leu Gly Glu Ala 545 550 555
560 Pro Gly Gly Gly Leu Phe Leu Pro Pro Pro Ser Pro Ile Gly Leu Pro
565 570 575 Gly Thr Pro Thr Tyr Tyr Asp Phe Lys Pro His Gln Asp Leu
Val Pro 580 585 590 Pro Cys Arg Leu Tyr Arg Ala Arg Ala Gly Tyr Leu
Thr Thr Pro His 595 600 605 Pro Arg Ala Phe Thr Ser Tyr Met Lys Pro
Thr Ser Phe Gly Pro Pro 610 615 620 Asp Leu Ser Ser Gly Thr Pro Pro
Phe Pro Tyr Ala Thr Leu Ser Pro 625 630 635 640 Pro Ser His Gln Arg
Leu Gln Thr His Val 645 650 5 2980 DNA Homo sapiens 5 cccagagacc
caggccgcgg aactggcagg cgtttcagag cgtcagaggc tgcggatgag 60
cagacttgga ggactccagg ccagagacta ggctgggcga agagtcgagc gtgaaggggg
120 ctccgggcca gggtgacagg aggcgtgctt gagaggaaga agttgacggg
aaggccagtg 180 cgacggcaaa tctcgtgaac cttgggggac gaatgctcag
gatgcgggtc cccgccctcc 240 tcgtcctcct cttctgcttc agagggagag
caggcccgtc gccccatttc ctgcaacagc 300 cagaggacct ggtggtgctg
ctgggggagg aagcccggct gccgtgtgct ctgggcgcct 360 actgggggct
agttcagtgg actaagagtg ggctggccct agggggccaa agggacctac 420
cagggtggtc ccggtactgg atatcaggga atgcagccaa tggccagcat gacctccaca
480 ttaggcccgt ggagctagag gatgaagcat catatgaatg tcaggctaca
caagcaggcc 540 tccgctccag accagcccaa ctgcacgtgc tggtcccccc
agaagccccc caggtgctgg 600 gcggcccctc tgtgtctctg gttgctggag
ttcctgcgaa cctgacatgt cggagccgtg 660 gggatgcccg ccctacccct
gaattgctgt ggttccgaga tggggtcctg ttggatggag 720 ccaccttcca
tcagaccctg ctgaaggaag ggacccctgg gtcagtggag agcaccttaa 780
ccctgacccc tttcagccat gatgatggag ccacctttgt ctgccgggcc cggagccagg
840 ccctgcccac aggaagagac acagctatca cactgagcct gcagtacccc
ccagaggtga 900 ctctgtctgc ttcgccacac actgtgcagg agggagagaa
ggtcattttc ctgtgccagg 960 ccacagccca gcctcctgtc acaggctaca
ggtgggcaaa agggggctct ccggtgctcg 1020 gggcccgcgg gccaaggtta
gaggtcgtgg cagacgcctc gttcctgact gagcccgtgt 1080 cctgcgaggt
cagcaacgcc gtgggtagcg ccaaccgcag tactgcgctg gatgtgctgt 1140
ttgggccgat tctgcaggca aagccggagc ccgtgtccgt ggacgtgggg gaagacgctt
1200 ccttcagctg cgcctggcgc gggaacccgc ttccacgggt aacctggacc
cgccgcggtg 1260 gcgcgcaggt gctgggctct ggagccacac tgcgtcttcc
gtcggtgggg cccgaggacg 1320 caggcgacta tgtgtgcaga gctgaggctg
ggctatcggg cctgcggggc ggcgccgcgg 1380 aggctcggct gactgtgaac
gctcccccag tagtgaccgc cctgcactct gcgcctgcct 1440 tcctgagggg
ccctgctcgc ctccagtgtc
tggttttcgc ctctcccgcc ccagatgccg 1500 tggtctggtc ttgggatgag
ggcttcctgg aggcggggtc gcagggccgg ttcctggtgg 1560 agacattccc
tgccccagag agccgcgggg gactgggtcc gggcctgatc tctgtgctac 1620
acatttcggg gacccaggag tctgacttta gcaggagctt taactgcagt gcccggaacc
1680 ggctgggcga gggaggtgcc caggccagcc tgggccgtag agacttgctg
cccactgtgc 1740 ggatagtggc cggagtggcc gctgccacca caactctcct
tatggtcatc actggggtgg 1800 ccctctgctg ctggcgccac agcaaggcct
cagcctcttt ctccgagcaa aagaacctga 1860 tgcgaatccc tggcagcagc
gacggctcca gttcacgagg tcctgaagaa gaggagacag 1920 gcagccgcga
ggaccggggc cccattgtgc acactgacca cagtgatctg gttctggagg 1980
agaaagggac tctggagacc aaggacccaa ccaacggtta ctacaaggtc cgaggagtca
2040 gtgtgagcct gagccttggc gaagcccctg gaggaggtct cttcctgcca
ccaccctccc 2100 cccttgggcc cccagggacc cctaccttct atgacttcaa
cccacacctg ggcatggtcc 2160 ccccctgcag actttacaga gccagggcag
gctatctcac cacaccccac cctcgagctt 2220 tcaccagcta catcaaaccc
acatcctttg ggcccccaga tctggccccc gggactcccc 2280 ccttcccata
tgctgccttc cccacaccta gccacccgcg tctccagact cacgtgtgac 2340
atctttccaa tggaagagtc ctgggatctc caacttgcca taatggattg ttctgatttc
2400 tgaggcgcca ggacaagttg gcgaccttac tcctccaaaa ctgaacacaa
ggggagggaa 2460 agatcattac atttgtcagg agcatttgta tacagtcagc
tcagccaaag gagatgcccc 2520 aagtgggagc aacatggcca cccaatatgc
ccacctattc cccggtgtaa aagagattca 2580 agatggcagg taggcccttt
gaggagagat ggggacaggg cagtgggtgt tgggagtttg 2640 gggccgggat
ggaagttgtt tctagccact gaaagaagat atttcaagat gaccatctgc 2700
attgagagga aaggtagcat aggatagatg aagatgaaga gcataccagg ccccaccctg
2760 gctctccctg aggggaactt tgctcggcca atggaaatgc agccaagatg
gccatatact 2820 ccctaggaac ccaagatggc caccatcttg attttacttt
ccttaaagac tcagaaagac 2880 ttggacccaa ggagtgggga tacagtgaga
attaccactg ttggggcaaa atattgggat 2940 aaaaatattt atgtttaata
ataaaaaaaa gtcaaagagg 2980 6 708 PRT Homo sapiens 6 Met Leu Arg Met
Arg Val Pro Ala Leu Leu Val Leu Leu Phe Cys Phe 1 5 10 15 Arg Gly
Arg Ala Gly Pro Ser Pro His Phe Leu Gln Gln Pro Glu Asp 20 25 30
Leu Val Val Leu Leu Gly Glu Glu Ala Arg Leu Pro Cys Ala Leu Gly 35
40 45 Ala Tyr Trp Gly Leu Val Gln Trp Thr Lys Ser Gly Leu Ala Leu
Gly 50 55 60 Gly Gln Arg Asp Leu Pro Gly Trp Ser Arg Tyr Trp Ile
Ser Gly Asn 65 70 75 80 Ala Ala Asn Gly Gln His Asp Leu His Ile Arg
Pro Val Glu Leu Glu 85 90 95 Asp Glu Ala Ser Tyr Glu Cys Gln Ala
Thr Gln Ala Gly Leu Arg Ser 100 105 110 Arg Pro Ala Gln Leu His Val
Leu Val Pro Pro Glu Ala Pro Gln Val 115 120 125 Leu Gly Gly Pro Ser
Val Ser Leu Val Ala Gly Val Pro Ala Asn Leu 130 135 140 Thr Cys Arg
Ser Arg Gly Asp Ala Arg Pro Thr Pro Glu Leu Leu Trp 145 150 155 160
Phe Arg Asp Gly Val Leu Leu Asp Gly Ala Thr Phe His Gln Thr Leu 165
170 175 Leu Lys Glu Gly Thr Pro Gly Ser Val Glu Ser Thr Leu Thr Leu
Thr 180 185 190 Pro Phe Ser His Asp Asp Gly Ala Thr Phe Val Cys Arg
Ala Arg Ser 195 200 205 Gln Ala Leu Pro Thr Gly Arg Asp Thr Ala Ile
Thr Leu Ser Leu Gln 210 215 220 Tyr Pro Pro Glu Val Thr Leu Ser Ala
Ser Pro His Thr Val Gln Glu 225 230 235 240 Gly Glu Lys Val Ile Phe
Leu Cys Gln Ala Thr Ala Gln Pro Pro Val 245 250 255 Thr Gly Tyr Arg
Trp Ala Lys Gly Gly Ser Pro Val Leu Gly Ala Arg 260 265 270 Gly Pro
Arg Leu Glu Val Val Ala Asp Ala Ser Phe Leu Thr Glu Pro 275 280 285
Val Ser Cys Glu Val Ser Asn Ala Val Gly Ser Ala Asn Arg Ser Thr 290
295 300 Ala Leu Asp Val Leu Phe Gly Pro Ile Leu Gln Ala Lys Pro Glu
Pro 305 310 315 320 Val Ser Val Asp Val Gly Glu Asp Ala Ser Phe Ser
Cys Ala Trp Arg 325 330 335 Gly Asn Pro Leu Pro Arg Val Thr Trp Thr
Arg Arg Gly Gly Ala Gln 340 345 350 Val Leu Gly Ser Gly Ala Thr Leu
Arg Leu Pro Ser Val Gly Pro Glu 355 360 365 Asp Ala Gly Asp Tyr Val
Cys Arg Ala Glu Ala Gly Leu Ser Gly Leu 370 375 380 Arg Gly Gly Ala
Ala Glu Ala Arg Leu Thr Val Asn Ala Pro Pro Val 385 390 395 400 Val
Thr Ala Leu His Ser Ala Pro Ala Phe Leu Arg Gly Pro Ala Arg 405 410
415 Leu Gln Cys Leu Val Phe Ala Ser Pro Ala Pro Asp Ala Val Val Trp
420 425 430 Ser Trp Asp Glu Gly Phe Leu Glu Ala Gly Ser Gln Gly Arg
Phe Leu 435 440 445 Val Glu Thr Phe Pro Ala Pro Glu Ser Arg Gly Gly
Leu Gly Pro Gly 450 455 460 Leu Ile Ser Val Leu His Ile Ser Gly Thr
Gln Glu Ser Asp Phe Ser 465 470 475 480 Arg Ser Phe Asn Cys Ser Ala
Arg Asn Arg Leu Gly Glu Gly Gly Ala 485 490 495 Gln Ala Ser Leu Gly
Arg Arg Asp Leu Leu Pro Thr Val Arg Ile Val 500 505 510 Ala Gly Val
Ala Ala Ala Thr Thr Thr Leu Leu Met Val Ile Thr Gly 515 520 525 Val
Ala Leu Cys Cys Trp Arg His Ser Lys Ala Ser Ala Ser Phe Ser 530 535
540 Glu Gln Lys Asn Leu Met Arg Ile Pro Gly Ser Ser Asp Gly Ser Ser
545 550 555 560 Ser Arg Gly Pro Glu Glu Glu Glu Thr Gly Ser Arg Glu
Asp Arg Gly 565 570 575 Pro Ile Val His Thr Asp His Ser Asp Leu Val
Leu Glu Glu Lys Gly 580 585 590 Thr Leu Glu Thr Lys Asp Pro Thr Asn
Gly Tyr Tyr Lys Val Arg Gly 595 600 605 Val Ser Val Ser Leu Ser Leu
Gly Glu Ala Pro Gly Gly Gly Leu Phe 610 615 620 Leu Pro Pro Pro Ser
Pro Leu Gly Pro Pro Gly Thr Pro Thr Phe Tyr 625 630 635 640 Asp Phe
Asn Pro His Leu Gly Met Val Pro Pro Cys Arg Leu Tyr Arg 645 650 655
Ala Arg Ala Gly Tyr Leu Thr Thr Pro His Pro Arg Ala Phe Thr Ser 660
665 670 Tyr Ile Lys Pro Thr Ser Phe Gly Pro Pro Asp Leu Ala Pro Gly
Thr 675 680 685 Pro Pro Phe Pro Tyr Ala Ala Phe Pro Thr Pro Ser His
Pro Arg Leu 690 695 700 Gln Thr His Val 705 7 2976 DNA Homo sapiens
7 gggaactggc aggcgtttca gagcgtcaga ggctgcggat gagcagactt ggaggactcc
60 aggccagaga ctaggctggg cgaagagtcg agcgtgaagg gggctccggg
ccagggtgac 120 aggaggcgtg cttgagagga agaagttgac gggaaggcca
gtgcgacggc aaatctcgtg 180 aaccttgggg gacgaatgct caggatgcgg
gtccccgccc tcctcgtcct cctcttctgc 240 ttcagaggga gagcaggccc
gtcgccccat ttcctgcaac agccagagga cctggtggtg 300 ctgctggggg
aggaagcccg gctgccgtgt gctctgggcg cctactgggg gctagttcag 360
tggactaaga gtgggctggc cctagggggc caaagggacc taccagggtg gtcccggtac
420 tggatatcag ggaatgcagc caatggccag catgacctcc acattaggcc
cgtggagcta 480 gaggatgaag catcatatga atgtcaggct acacaagcag
gcctccgctc cagaccagcc 540 caactgcacg tgctggtccc cccagaagcc
ccccaggtgc tgggcggccc ctctgtgtct 600 ctggttgctg gagttcctgc
gaacctgaca tgtcggagcc gtggggatgc ccgccctgcc 660 cctgaattgc
tgtggttccg agatggggtc ctgttggatg gagccacctt ccatcagacc 720
ctgctgaagg aagggacccc tgggtcagtg gagagcacct taaccctgac cccctttcag
780 ccatgatgat ggagccacct ttgtctgccg ggcccggagc caggccctgc
ccacaggaag 840 agacacagct atcacactga gcctgcagta ccccccagag
gtgactctgt ctgcttcgcc 900 acacactgtg caggagggag agaaggtcat
tttcctgtgc caggccacag cccagcctcc 960 tgtcacaggc tacaggtggg
caaaaggggg ctctccggtg ctcggggccc gcgggccaag 1020 gttagaggtc
gtggcagacg cctcgttcct gactgagccc gtgtcctgcg aggtcagcaa 1080
cgccgtgggt agcgccaacc gcagtactgc gctggatgtg ctgtttgggc cgattctgca
1140 ggcaaagccg gagcccgtgt ccgtggacgt gggggaagac gcttccttca
gctgcgcctg 1200 gcgcgggaac ccgcttccac gggtaacctg gacccgccgc
ggtggcgcgc aggtgctggg 1260 ctctggagcc acactgcgtc ttccgtcggt
ggggcccgag gacgcaggcg actatgtgtg 1320 cagagctgag gctgggctat
cgggcctgcg gggcggcgcc gcggaggctc ggctgactgt 1380 gaacgctccc
ccagtagtga ccgccctgca ctctgcgcct gccttcctga ggggccctgc 1440
tcgcctccag tgtctggttt tcgcctctcc cgccccagat gccgtggtct ggtcttggga
1500 tgagggcttc ctggaggcgg ggtcgcaggg ccggttcctg gtggagacat
tccctgcccc 1560 agagagccgc gggggactgg gtccgggcct gatctctgtg
ctacacattt cggggaccca 1620 ggagtctgac tttagcagga gctttaactg
cagtgcccgg aaccggctgg gcgagggagg 1680 tgcccaggcc agcctgggcc
gtagagactt gctgcccact gtgcggatag tggccggagt 1740 ggccgctgcc
accacaactc tccttatggt catcactggg gtggccctct gctgctggcg 1800
ccacagcaag gcctcagcct ctttctccga gcaaaagaac ctgatgcgaa tccctggcag
1860 cagcgacggc tccagttcac gaggtcctga agaagaggag acaggcagcc
gcgaggaccg 1920 gggccccatt gtgcacactg accacagtga tctggttctg
gaggaggaag ggactctgga 1980 gaccaaggac ccaaccaacg gttactacaa
ggtccgagga gtcagtgtga gcctgagcct 2040 tggcgaagcc cctggaggag
gtctcttcct gccaccaccc tccccccttg ggcccccagg 2100 gacccctacc
ttctatgact tcaacccaca cctgggcatg gtccccccct gcagacttta 2160
cagagccagg gcaggctatc tcaccacacc ccaccctcga gctttcacca gctacatcaa
2220 acccacatcc tttgggcccc cagatctggc ccccgggact ccccccttcc
catatgctgc 2280 cttccccaca cctagccacc cgcgtctcca gactcacgtg
tgacatcttt ccaatggaag 2340 agtcctggga tctccaactt gccatcctgg
attgttctga tttctgagga gccaggacaa 2400 gttggcgacc ttactcctcc
aaaactgaac acaaggggag ggaaagatca ttacatttgt 2460 caggagcatt
tgtatacagt cagctcagcc aaaggagatg ccccaagtgg gagcaacatg 2520
gccacccaat atgcccacct attccccggt gtaaaagaga ttcaagatgg caggtaggcc
2580 ctttgaggag agatggggac agggcagtgg gtgttgggag tttggggccg
ggatggaagt 2640 tgtttctagc cactgaaaga agatatttca agatgaccat
ctgcattgag aggaaaggta 2700 gcataggata gatgaagatg aagagcatac
caggccccac cctggctctc cctgagggga 2760 actttgctcg gccaatggaa
atgcagccaa gatggccata tactccctag gaacccaaga 2820 tggccaccat
cttgatttta ctttccttaa agacacagaa agacttggac ccaaggagtg 2880
gggatacagt gagaattacc actgttgggg caaaatattg ggataaaaat atttatgttt
2940 aataataaaa aaaagtcaaa aaaaaaaaaa aaaaaa 2976 8 196 PRT Homo
sapiens 8 Met Leu Arg Met Arg Val Pro Ala Leu Leu Val Leu Leu Phe
Cys Phe 1 5 10 15 Arg Gly Arg Ala Gly Pro Ser Pro His Phe Leu Gln
Gln Pro Glu Asp 20 25 30 Leu Val Val Leu Leu Gly Glu Glu Ala Arg
Leu Pro Cys Ala Leu Gly 35 40 45 Ala Tyr Trp Gly Leu Val Gln Trp
Thr Lys Ser Gly Leu Ala Leu Gly 50 55 60 Gly Gln Arg Asp Leu Pro
Gly Trp Ser Arg Tyr Trp Ile Ser Gly Asn 65 70 75 80 Ala Ala Asn Gly
Gln His Asp Leu His Ile Arg Pro Val Glu Leu Glu 85 90 95 Asp Glu
Ala Ser Tyr Glu Cys Gln Ala Thr Gln Ala Gly Leu Arg Ser 100 105 110
Arg Pro Ala Gln Leu His Val Leu Val Pro Pro Glu Ala Pro Gln Val 115
120 125 Leu Gly Gly Pro Ser Val Ser Leu Val Ala Gly Val Pro Ala Asn
Leu 130 135 140 Thr Cys Arg Ser Arg Gly Asp Ala Arg Pro Ala Pro Glu
Leu Leu Trp 145 150 155 160 Phe Arg Asp Gly Val Leu Leu Asp Gly Ala
Thr Phe His Gln Thr Leu 165 170 175 Leu Lys Glu Gly Thr Pro Gly Ser
Val Glu Ser Thr Leu Thr Leu Thr 180 185 190 Pro Phe Gln Pro 195 9
1532 DNA Homo sapiens 9 cccagagacc caggccgcgg aactggcagg cgtttcagag
cgtcagaggc tgcggatgag 60 cagacttgga ggactccagg ccagagacta
ggctgggcga agagtcgagc gtgaaggggg 120 ctccgggcca gggtgacagg
aggcgtgctt gagaggaaga agttgacggg aaggccagtg 180 cgacggcaaa
tctcgtgaac cttgggggac gaatgctcag gatgcgggtc cccgccctcc 240
tcgtcctcct cttctgcttc agagggagag caggcccgtc gccccatttc ctgcaacagc
300 cagaggacct ggtggtgctg ctgggcgagg gaggtgccca ggccagcctg
ggccgtagag 360 cctcagcctc tttctccgag caaaagaacc tgatgcgaat
ccctggcagc agcgacggct 420 ccagttcacg aggtcctgaa gaagaggaga
caggcagccg cgaggaccgg ggccccattg 480 tgcacactga ccacagtgat
ctggttctgg aggaggaagg gactctggag accaaggacc 540 caaccaacgg
ttactacaag gtccgaggag tcagtgtgag cctgagcctt ggcgaagccc 600
ctggaggagg tctcttcctg ccaccaccct ccccccttgg gcccccaggg acccctacct
660 tctatgactt caacccacac ctgggcatgg tccccccctg cagactttac
agagccaggg 720 caggctctct caccacaccc caccctcgag ctttcaccag
ctacatcaaa cccacatcct 780 ttgggccccc agatctggcc cccgggactc
cccccttccc atatgctgcc ttccccacac 840 ctagccaccc gcgtctccag
actcacgtgt gacatctttc caatggaaga gtcctgggat 900 ctccaacttg
ccataatgga ttgttctgat ttctgaggag ccaggacaag ttggcgacct 960
tactcctcca aaactgaaca caaggggagg gaaagatcat tacatttgtc aggagcattt
1020 gtatacagtc agctcagcca aaggagatgc cccaagtggg agcaacatgg
ccacccaata 1080 tgcccaccta ttccccggtg taaaagagat tcaagatggc
aggtaggccc tttgaggaga 1140 gatggggaca gggcagtggg tgttgggagt
ttggggccgg gatggaagtt gtttctagcc 1200 actgaaagaa gatatttcaa
gatgaccatc tgcattgaga ggaaaggtag cataggatag 1260 atgaagatga
agagcatacc aggccccacc ctggctctcc ctgaggggaa ctttgctcgg 1320
ccaatggaaa tgcagccaag atggccatat actccctagg aacccaagat ggccaccatc
1380 ttgattttac tttccttaaa gactcagaaa gacttggacc caaggagtgg
ggatacagtg 1440 agaattacca ctgttggggc aaaatattgg gataaaaata
tttatgttta ataataaaaa 1500 aaagtcaaag aggcaaaaaa aaaaaaaaaa aa 1532
10 219 PRT Homo sapiens 10 Met Leu Arg Met Arg Val Pro Ala Leu Leu
Val Leu Leu Phe Cys Phe 1 5 10 15 Arg Gly Arg Ala Gly Pro Ser Pro
His Phe Leu Gln Gln Pro Glu Asp 20 25 30 Leu Val Val Leu Leu Gly
Glu Gly Gly Ala Gln Ala Ser Leu Gly Arg 35 40 45 Arg Ala Ser Ala
Ser Phe Ser Glu Gln Lys Asn Leu Met Arg Ile Pro 50 55 60 Gly Ser
Ser Asp Gly Ser Ser Ser Arg Gly Pro Glu Glu Glu Glu Thr 65 70 75 80
Gly Ser Arg Glu Asp Arg Gly Pro Ile Val His Thr Asp His Ser Asp 85
90 95 Leu Val Leu Glu Glu Glu Gly Thr Leu Glu Thr Lys Asp Pro Thr
Asn 100 105 110 Gly Tyr Tyr Lys Val Arg Gly Val Ser Val Ser Leu Ser
Leu Gly Glu 115 120 125 Ala Pro Gly Gly Gly Leu Phe Leu Pro Pro Pro
Ser Pro Leu Gly Pro 130 135 140 Pro Gly Thr Pro Thr Phe Tyr Asp Phe
Asn Pro His Leu Gly Met Val 145 150 155 160 Pro Pro Cys Arg Leu Tyr
Arg Ala Arg Ala Gly Tyr Leu Thr Thr Pro 165 170 175 His Pro Arg Ala
Phe Thr Ser Tyr Ile Lys Pro Thr Ser Phe Gly Pro 180 185 190 Pro Asp
Leu Ala Pro Gly Thr Pro Pro Phe Pro Tyr Ala Ala Phe Pro 195 200 205
Thr Pro Ser His Pro Arg Leu Gln Thr His Val 210 215 11 26 DNA
Artificial Sequence Adapter for cDNA amplification 11 cagctccaca
acctacatca ttccgt 26 12 12 DNA Artificial Sequence Adapter for cDNA
amplification 12 acggaatgat gt 12 13 26 DNA Artificial Sequence
Adapter for cDNA amplification 13 gtccatcttc tctctgagac tctggt 26
14 12 DNA Artificial Sequence Adapter for cDNA amplification 14
accagagtct ca 12 15 26 DNA Artificial Sequence Adapter for cDNA
amplification 15 ctgatgggtg tcttctgtga gtgtgt 26 16 12 DNA
Artificial Sequence Adapter for cDNA amplification 16 acacactcac ag
12 17 26 DNA Artificial Sequence Adapter for cDNA amplification 17
ccagcatcga gaatcagtgt gacagt 26 18 12 DNA Artificial Sequence
Adapter for cDNA amplification 18 actgtcacac tg 12 19 26 DNA
Artificial Sequence Adapter for cDNA amplification 19 gtcgatgaac
ttcgactgtc gatcgt 26 20 12 DNA Artificial Sequence Adapter for cDNA
amplification 20 acgatcgaca gt 12 21 26 DNA Artificial Sequence
Primer for RACE method 21 ggctttacac tttatgcttc cggctc 26 22 26 DNA
Artificial Sequence Primer for RACE method 22 cagctatgac catgattacg
ccaagc 26 23 26 DNA Artificial Sequence Primer for RACE method 23
aggcgattaa gttgggtaac gccagg 26 24 26 DNA Artificial Sequence
Primer for RACE method 24 ccagtcacga cgttgtaaaa cgacgg 26 25 26 DNA
Artificial Sequence Primer for RACE method 25 cttcccgtat gctaccttgt
ctccac 26 26 26 DNA Artificial Sequence Primer for RACE method 26
tccatctctc caagtgaagg gtcttg 26 27 26 DNA Artificial Sequence
Primer for RACE method 27 ccaacagtcc tgcatgcttg taatga 26 28 26 DNA
Artificial
Sequence Primer for RACE method 28 tccttcaatg ttcagttttg gagggg
26
* * * * *
References